Котельная установка

Полезная модель относится к котлостроению. Может быть использована при проектировании и изготовлении котлов, в том числе судовых.Котельная установка включает котел с газоходом, к которому подключен газоанализатор, а также топливную система котла, содержащую последовательно соединенные переключатель вида топлива, топливный насос, фильтр грубой очистки, подогреватель топлива, фильтр тонкой очистки, а также цистерну нефтеостатков и расходную цистерну, при этом один вход переключателя вида топлива подключен к расходной цистерне, а другой - к цистерне нефтеостатков, кроме того, содержит последовательно соединенные цистерну пресной воды, насос и регулируемый клапан, а котел содержит двухканальную форсунку, первый канал которой подключен к выходу фильтра тонкой очистки, а второй к выходу регулируемого клапана. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 188 303 U1 (51) МПК F22B 31/00 (2006.01) F22B 33/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (52) СПК F22B 31/00 (2018.08) (21)(22) Заявка: 2018141463, 26.11.2018 (24) Дата начала отсчета срока действия патента: Дата регистрации: 05.04.2019 (45) Опубликовано: 05.04.2019 Бюл. № 10 1 8 8 3 0 3 R U (54) Котельная установка (57) Реферат: Полезная модель относится к котлостроению. Может быть использована при проектировании и изготовлении котлов, в том числе судовых. Котельная установка включает котел с газоходом, к которому подключен газоанализатор, а также топливную система котла, содержащую последовательно соединенные переключатель вида топлива, топливный насос, фильтр грубой очистки, подогреватель топлива, фильтр тонкой очистки, Стр.: 1 (56) Список документов, цитированных в отчете о поиске: RU 182397 U1, 15.08.2018. RU 58665 U1, 27.11.2006. RU 81786 U1, 27.03.2009. RU 2637609 C2, 05.12.2017. US 4701124 A1, 20.10.1987. а также цистерну нефтеостатков и расходную цистерну, при этом один вход переключателя вида топлива подключен к расходной цистерне, а другой - к цистерне ...

System for the Heating of Two Mutually Separated Liquids

The invention relates to a system for heating two mutually separated liquids, wherein a first liquid is intended for heating a building and wherein the second liquid is tap water. 1. A system for heating two mutually separated liquids , wherein a first liquid is intended for heating a building and wherein the second liquid is tap water , which system comprises: a housing with an air feed, a fuel feed and a flue gas discharge;', 'a burner disposed in the housing for combusting fuel and air supplied to the burner while releasing flue gases, which burner is connected on the one hand for medium throughflow to the fuel feed and the air feed and is connected on the other for medium throughflow to the flue gas discharge;', 'a first heat exchanger connected for medium throughflow to the flue gas discharge for the purpose of transferring heat from the flue gases to the first liquid in order to heat the first liquid;, 'a device for heating the first liquid, the device comprisinga second heat exchanger disposed downstream of the first heat exchanger for transferring residual heat from the flue gases to the tap water in order to preheat the tap water;a third heat exchanger disposed downstream of the first heat exchanger and the second heat exchanger for transferring heat from the first liquid to the preheated tap water in order to further heat the preheated tap water,characterized bya reservoir for storing tap water, which reservoir is disposed downstream of the third heat exchanger and connected for medium throughflow thereto by means of a first conduit, wherein the conduit debouches in an upper part of the reservoir such that the tap water heated in the third heat exchanger is delivered during use into the upper part of the reservoir, and wherein the reservoir is on the other hand connected for medium throughflow by means of a second conduit to the second heat exchanger and disposed upstream thereof, which second conduit is connected to a lower part of the reservoir for the ...

Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens. 120-. (canceled)21. A method of treating non-metastatic castration-resistant prostate cancer in a male human comprising administering a second-generation anti-androgen to a male human in need of such treatment , wherein the second-generation anti-androgen is administered in combination with a gonadotropin-releasing hormone (GnRH) agonist or antagonist or orchiectomy.22. The method of claim 21 , wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer.23. The method of claim 21 , wherein the second-generation anti-androgen is administered in combination with the GnRH agonist or antagonist.24. The method of claim 21 , wherein the second-generation anti-androgen is administered in combination with the GnRH agonist and the GnRH agonist is leuprolide claim 21 , buserelin claim 21 , nafarelin claim 21 , histrelin claim 21 , goserelin claim 21 , or deslorelin.25. The method of claim 21 , wherein the second-generation anti-androgen is administered post-orchiectomy.26. The method of claim 21 , wherein the male human previously received a first-generation anti-androgen claim 21 , and wherein the first-generation anti-androgen is bicalutamide claim 21 , flutamide or nilutamide.27. The method of claim 21 , wherein the second-generation anti-androgen is administered daily to the male human.28. The method of claim 21 , wherein the second-generation anti-androgen is administered orally to the male human.29. The method of claim 21 , wherein the second-generation anti-androgen is administered orally to the male human on a continuous daily dosing schedule.30. The method of claim 21 , wherein the second-generation anti-androgen is administered orally to the male human at a dose of about 600 mg.31. The method of claim 21 , wherein the second-generation anti-androgen is administered orally to the male ...

ONYCHOMYCOSIS TREATMENT SYSTEM AND METHOD

A system and method includes a nonthermal plasma sub-system with a permeable UV filter for production and delivery of a redox gas solution to treat onychomycosis, wherein the redox gas solution comprises a reactive species dissolved in a perfluorocarbon liquid, and wherein the perfluorocarbon liquid is dispensed onto a gas-permeable membrane and wherein the reactive species may include, alone or in combination, one or more of reactive oxygen, reactive nitrogen, reactive chlorine, or reactive bromine species, and the perfluorocarbon liquid may include perfluorodecalin. 1. A method of treating an infection on a body part comprising:a) applying a perfluorocarbon to a body part with an infection,b) positioning said body part in a chamber,c) Said chamber having a venting louver,d) Said venting louver having holes disposed in said venting louver passing through said venting louver,e) Said chamber having a nonthermal plasma subunitf) Said nonthermal plasma subunit disposed within said chamber such that said body part is proximal to said venting louver and said venting louver is proximal to said nonthermal plasma subunit,g) Said nonthermal plasma subunit assembly comprising an electrical control circuit, a high voltage electrode, a dielectric barrier, and a ground electrode,h) Said nonthermal plasma subunit having a plasma gas permeable UV filter disposed proximate to said plasma head assembly,{'sub': '2', 'i) Said gas permeable UV filter having TiOcompounds attached to the surface of said gas permeable UV filter,'}j) Said gas permeable UV filter having anti-fungal compounds attached to the surface of said gas permeable UV filter,k) Said plasma head assembly capable of forming a plasma reactive species proximate to said ground electrode,l) Said plasma head producing a reactive species which is in communication with said perfluorocarbon by passing between said plasma head assembly through the said holes in said venting louver to the focus said reactive species on said ...

METHODS TO TREAT ALLERGIC CONDITIONS

Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3. 1. A method to treat an allergic condition in a subject who has or is at risk of having an allergic condition , comprising administering to the subject a composition that inhibits Pim1 kinase.2. The method of claim 1 , wherein the allergic condition is selected from the group consisting of allergic rhinitis claim 1 , asthma claim 1 , airway hyperresponsiveness claim 1 , airway inflammation claim 1 , a food allergy claim 1 , eosinophilic esophagitis claim 1 , chronic urticaria claim 1 , atopic dermatitis claim 1 , occupational allergy claim 1 , allergic conjunctivitis claim 1 , hay fever claim 1 , airborne allergic sensitivities claim 1 , stinging insect allergy claim 1 , hypersensitivity pneumonitis claim 1 , eosinophilic lung diseases claim 1 , inflammatory bowel disease claim 1 , ulcerative colitis claim 1 , Crohn's disease and drug allergies.3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. The method of claim 1 , wherein the subject has been sensitized to an allergen and has been exposed to claim 1 , or is at risk of being exposed to claim 1 , the allergen.8. (canceled)9. The method of claim 1 , wherein the composition comprises a compound selected from the group consisting of a small molecule inhibitor claim 1 , an antibody claim 1 , a chemical entity claim 1 , a nucleotide claim 1 , a peptide claim 1 , and a protein.10. (canceled)11. The method of claim 9 , wherein the small molecule inhibitor is a Pim1 kinase inhibitor.12. (canceled)13. The method of claim 11 , wherein administration of the Pim1 kinase inhibitor induces expression of Runx3.14. The method of claim 11 , wherein administration of the Pim1 kinase inhibitor reduces or supresses CD4 and CD8 ...

METHOD OF TREATMENT OF AGGRESSION

The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity. 112.-. (canceled)13. A method of treating impulsive aggression in an attention deficit hyperactivity disorder (ADHD) patient , comprising: administering 36 mg/day of molindone to a patient with ADHD as the sole condition and manifesting impulsive aggression not controlled by ADHD treatment.14. The method of anyone of claim 13 , wherein the administration decreases side effects associated with molindone.15. The method of claim 14 , wherein the side effects are selected from drowsiness claim 14 , depression claim 14 , hyperactivity claim 14 , euphoria claim 14 , extrapyramidal reactions claim 14 , akathisia claim 14 , akinesia claim 14 , dystonic syndrome claim 14 , tardive dyskinesia claim 14 , tachycardia claim 14 , nausea claim 14 , dry mouth claim 14 , urinary retention claim 14 , and constipation.16. The method of anyone of claim 13 , wherein the administration results in reduction of undesirable behavior and intolerable side effects.17. The method of anyone of claim 13 , wherein the patient is a child.18. A method of treating impulsive aggression in an attention deficit hyperactivity disorder (ADHD) patient claim 13 , comprising: administering 54 mg/day of molindone to a patient with ADHD as the sole condition and manifesting impulsive aggression not controlled by ADHD treatment.19. The method of anyone of claim 18 , wherein the administration decreases side effects associated with molindone.20. The method of claim 19 , wherein the side effects are selected from drowsiness claim 19 , depression claim 19 , hyperactivity claim 19 , euphoria claim 19 , extrapyramidal reactions claim 19 , akathisia claim 19 , akinesia claim 19 , dystonic syndrome claim 19 , tardive dyskinesia claim 19 , tachycardia claim 19 , nausea claim 19 , dry mouth claim 19 , urinary ...

HEATING AND HOT WATER SUPPLY SYSTEM

The system includes: a heat pump unit; a hot water supply heat exchanger; heating heat exchangers; a pump; heat medium pipes that connect a discharge side of the pump, the heat pump unit, the hot water supply heat exchanger, the heating heat exchangers, and a suction side of the pump in order; a first bypass pipe that bypasses the hot water supply heat exchanger from the heat medium pipe; a second bypass pipe that bypasses the heating heat exchangers from the heat medium pipe; a four-way valve that regulates flow distribution of the heat medium between the hot water supply heat exchanger and the first bypass pipe and between the heating heat exchangers and the second bypass pipe; and a control unit for controlling the four-way valve in accordance with a hot water supply request and a heating request. 1. A heating and hot water supply system comprising:heating means for heating a heat medium;a hot water supply heat exchanger that performs heat exchange between the heat medium and water;a hot water storage tank that stores water heated by the hot water supply heat exchanger;a heating heat exchanger that heats an inside of a room using the heat medium;a heat medium pump that feeds the heat medium;a circulation pipe that annularly connects a discharge side of the heat medium pump, the heating means, the hot water supply heat exchanger, the heating heat exchanger, and a suction side of the heat medium pump in order;a first bypass pipe that bypasses the hot water supply heat exchanger from the circulation pipe;a second bypass pipe that bypasses the heating heat exchanger from the circulation pipe;first flow regulating means that is provided at a junction between the circulation pipe and the first bypass pipe, and regulates a ratio between a flow rate of the heat medium flowing into the hot water supply heat exchanger and a flow rate of the heat medium flowing into the first bypass pipe;a second flow regulating means that is provided at a junction between the circulation ...

DUAL FUNCTION DOMESTIC HOT WATER PREHEATER AND INTEGRATED SPACE HEATER

Embodiments described herein generally relate to a domestic hot water (DHW) preheater operable to supply domestic hot water to a structure and/or to preheat a cold return of a space heating system. 1. An apparatus comprising:a boiler having an inlet and an outlet, the boiler configured to supply heated fluid to a space heating circuit via the outlet; anda water heater configured to supply domestic hot water, cold fluid from the space heating circuit configured to be preheated by the water heater before entering the inlet of the boiler.2. The apparatus of claim 1 , wherein the water heater includes:a tank configured to contain domestic hot water; anda heat exchanger configured to transfer heat from the domestic hot water to the cold fluid from the space heating circuit.3. The apparatus of claim 1 , wherein the water heater is configured to heat water using an electric heater and a fossil fuel source.4. The apparatus of claim 3 , further comprising an electric immersion heater and a fossil fuel burner.5. The apparatus of claim 3 , further comprising a processor configured to:obtain a real-time electricity price, andselectively actuate one of the electric heater or the fossil fuel source based, at least in part, on the real-time electricity price.6. The apparatus of claim 1 , further comprising:an electric immersion heater configured to completely meet a predetermined peak demand for domestic hot water; anda fossil fuel source configured to completely meet the predetermined peak demand for domestic hot water.7. The apparatus of claim 6 , further comprising a processor configured to balance the electric immersion heater and the fossil fuel source based claim 6 , at least in part claim 6 , on a real-time electricity price.8. The apparatus of claim 1 , further comprising a closed water heater loop including a first heat exchanger immersed in a tank of the water heater and a second heat exchanger disposed outside the tank of the water heater claim 1 , the second heat ...

Treatment of Retinopathy of Prematurity (ROP)

Disclosed herein are methods of treating retinopathy of prematurity (ROP) in a premature and/or low birth weight infant in need thereof, comprising administering to the infant an effective amount of a compound represented by Structural Formula I, Structural Formula Ia or Structural Formula II described herein, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of inhibiting the destruction of retinal blood vessels in a premature and/or low birth weight infant in need thereof, comprising administering to the infant an effective amount of a compound represented by Structural Formula I, Structural Formula Ia or Structural Formula II, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating hyperoxia in a premature and/or low birth weight infant in need thereof, comprising administering to the infant an effective amount of a compound represented by Structural Formula I, Structural Formula Ia or Structural Formula II, or a pharmaceutically acceptable salt thereof. By using the methods disclosed herein, particularly when an infant is hyperoxic, oxygen toxicity to the retina of the eye can be inhibited without restricting oxygen supplementation, which is often necessary to sustain the life of premature infants. 5. The method of claim 1 , wherein the compound claim 1 , or pharmaceutically acceptable salt thereof claim 1 , is administered while the infant is in a hyperoxic state.6. The method of claim 1 , wherein the infant is a premature infant.7. The method of claim 1 , wherein the infant is a severely premature infant.8. The method of claim 1 , wherein the infant is a low birth weight infant.9. The method of claim 1 , wherein the compound claim 1 , or pharmaceutically acceptable salt thereof claim 1 , is administered systemically.10. The method of claim 9 , wherein the compound claim 9 , or pharmaceutically acceptable salt thereof claim 9 , is administered intraperitoneally claim 9 , intravenously or ...

HOT WATER SUPPLY AND HEATING SYSTEM

A hot water supply and heating system includes a heating flow rate changing valve that changes the flow rate of hot water flowing through a heating pipe and a priority controller that carries out hot water supply priority control whereby to reduce the flow rate of the hot water flowing through the heating pipe by the heating flow rate changing valve in the case where the total of the amount of heat consumed in a heating operation and the amount of heat consumed in a hot water supply operation is equal to or more than a maximum amount of heat that can be applied by the heat source machine during a simultaneous operation of the heating operation and the hot water supply operation. 1. A hot water supply and heating system comprising:a heat source machine which is connected to a water supply pipe and a hot water supply pipe to heat water flowing from the water supply pipe to the hot water supply pipe;a heating pipe which is branched off from the hot water supply pipe and which is in communication with the water supply pipe;a heater which is connected on a way of the heating pipe and which has a pump, which circulates water in the heating pipe via the heat source machine, and a radiator;a hot water supply bypass pipe which provides communication between a portion of the water supply pipe on an upstream side relative to a place where the water supply pipe is connected with the heating pipe and a portion of the hot water supply pipe on a downstream side relative to a place where the hot water supply pipe is connected with the heating pipe;a heating controller which is configured to actuate the pump in a state, wherein the heat source machine is in operation, thereby to carry out a heating operation in which heat is radiated from the radiator;a hot water supply controller which is configured to carry out a hot water supply operation by carrying out mixing temperature control whereby to adjust a mixing ratio of the hot water from the hot water supply pipe and the water from ...

METHODS AND MATERIALS FOR PROLONGED SWEAT STIMULATION

A method for stimulating and sensing sweat includes dosing a sweat stimulant to skin effective to generate sweat at a generation rate of at least 0.1 nL/min/gland for a duration of six hours or more per dose of the sweat stimulant, and sensing generated sweat using a device placed on the skin comprising at least one sensor specific to an analyte in sweat. The dosing comprises at least one of: applying a charge density of less than 320 mC/cm/day or applying a one-time dose of the sweat stimulant. 1. A method for stimulating and sensing sweat comprising:dosing a sweat stimulant to skin effective to generate sweat at a generation rate of at least 0.1 nL/min/gland for a duration of six hours or more per dose of the sweat stimulant; andsensing generated sweat using a device placed on the skin comprising at least one sensor specific to an analyte in sweat;{'sup': '2', 'wherein dosing comprises at least one of: applying a charge density that is equal to or less than 320 mC/cm/day or applying a one-time dose of the sweat stimulant.'}2. The method of claim 1 , wherein the generation rate is greater than 0.2 nL/min/gland for the duration of six hours.3. The method of claim 1 , wherein the generation rate is greater than 5 nL/min/gland for the duration of six hours.4. The method of claim 1 , wherein dosing includes applying a total charge density that is equal to or less than 160 mC/cm/day.5. The method of claim 1 , wherein dosing includes applying a total charge density that is equal to or less than 1 mC/cm/day.6. The method of claim 1 , wherein dosing includes applying a charge that is less than 20 mC/day.7. The method of claim 1 , wherein dosing includes applying a charge that is less than 1 mC/day.8. The method of claim 1 , wherein the generated sweat per gland that is greater than 5 claim 1 ,600 nL/gland/dose.9. The method of claim 1 , wherein the generated sweat per gland that is greater than 350 nL/gland/dose.10. The method of claim 1 , wherein the sweat stimulant ...

METHOD OF TREATMENT OF AGGRESSION

The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity. 1. A method of treating impulsive aggression in an attention deficit hyperactivity disorder (ADHD) patient , comprising:administering 10 mg/day to 200 mg/day of molindone to a patient with ADHD as the sole condition and manifesting impulsive aggression not controlled by ADHD treatment.2. The method of claim 1 , wherein 15 to 120 mg/day of molindone is administered.3. The method of claim 1 , wherein the administration decreases side effects associated with molindone.4. The method of claim 3 , wherein the side effects are selected from drowsiness claim 3 , depression claim 3 , hyperactivity claim 3 , euphoria claim 3 , extrapyramidal reactions claim 3 , akathisia claim 3 , akinesia claim 3 , dystonic syndrome claim 3 , tardive dyskinesia claim 3 , tachycardia claim 3 , nausea claim 3 , dry mouth claim 3 , urinary retention claim 3 , and constipation.5. The method of claim 1 , wherein the administration results in reduction of undesirable behavior and intolerable side effects.6. The method of claim 1 , wherein the patient is a child. This application is a Continuation of U.S. patent application Ser. No. 13/951,642, filed Jul. 26, 2013, which is a Continuation of U.S. application Ser. No. 12/654,455, filed Dec. 18, 2009, which claims priority from U.S. Provisional Application No. 61/193,735, filed Dec. 19, 2008, the entire contents of which are incorporated herein by reference.Aggression and similar syndromes, including impulsivity and irritability, represent a broad category of behaviors that complicate the management of several disease states, such as attention deficit hyperactivity disorder (ADHD), bipolar disorder, autism, and post traumatic stress disorder. In some cases, 25-50% of patients optimally treated for the underlying disorder continue to manifest ...

METHOD OF TREATMENT OF CNS DISORDERS

The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity. 19.-. (canceled)10. A method of treating a CNS disorder in a mammalian subject comprising:determining whether a pharmaceutical agent having known activity inhibiting noradrenergic, serotonergic and dopaminergic reuptake transporters also exhibits mu-opioid agonistic activity,determining a dose of the pharmaceutical agent that is effective to provide noradrenergic, serotonergic and dopaminergic reuptake transporter inhibitory activity together with mu-opioid receptor agonist activity in the mammalian subject, andadministering the effective dose of the pharmaceutical agent to the mammalian subject.11. The method of claim 10 , wherein the CNS disorder is ADHD and the pharmaceutical agent is mazindol.12. The method of claim 11 , wherein the effective dose is an oral daily dose of 0.1 to 0.5 mg of mazindol. Mazindol (5-(p-chloropheny)-2,5-dihydro-3H-imidazo[2,1-a] isoindol-5-ol) is a monoamine reuptake inhibitor originally marketed as Degonan by Slovakofarma (Czechoslovakia), Mazanor by Wyeth-Ayerst (USA), Mazindol by Polfa (Poland), Sanorex by Sandoz (USA), and Teronac by Wander (Germany and the UK). Mazindol was also approved under an orphan drug indication for Duschene Muscular Dystrophy in the USA.Mazindol has specific inhibitory binding activity at the dopamine, noradrenergic and serotonergic reuptake transporters as well as moderately potent binding at the H1 receptor. The present invention is predicated on the unexpected discovery that mazindol may be effective in the treatment of several CNS disorders with nominal, if any, side effects.In one aspect, the present invention provides a method of treatment of major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, autism, ...

INTEGRATED SPACE CONDITIONING AND WATER HEATING SYSTEMS AND METHODS THERETO

The disclosed technology includes an integrated system including a space conditioning system, a liquid heating system, and a controller. The space conditioning system can include a refrigerant circuit fluidly connecting a compressor, a first heat exchanger, a second heat exchanger, a third heat exchanger, an expansion valve, and a reversing valve such that refrigerant can flow through the circuit. The liquid heating system can include a liquid heating device and a liquid circuit configured to direct liquid from the liquid heating device through the first heat exchanger. The controller can be in electrical communication with the space conditioning system and the liquid heating system. The controller can be configured to determine a demand of the space conditioning system and the liquid heating system, and in response, output instructions to a plurality of valves to direct the refrigerant through the refrigerant circuit and direct the liquid through the liquid circuit. 1. A system for conditioning air and heating water comprising:a space conditioning system comprising a refrigerant circuit fluidly connecting a compressor, a first heat exchanger, a second heat exchanger, a third heat exchanger, an expansion valve, and a reversing valve, the refrigerant circuit comprising conduit and a plurality of valves configured to direct refrigerant along the refrigerant circuit;{'claim-text': ['a liquid heating device; and', 'a liquid circuit fluidly connecting the liquid heating device and the first heat exchanger, the liquid circuit (i) comprising conduit configured to direct liquid along the liquid circuit and (ii) being fluidly separate from the refrigerant circuit; and'], '#text': 'a liquid heating system comprising:'}{'claim-text': ['determine a demand of the space conditioning system;', 'determine a demand of the liquid heating system; and', 'in response to determining the demand of the space conditioning system and the demand of the liquid heating system, output ...

MEDICAL TREATMENTS BASED ON ANAMORELIN

Methods of treating cancer related conditions using anamorelin are described. 1) A method of treating cachexia in a human cancer patient having a body weight loss greater than or equal to 2% in the previous 6 months and a body mass index less than 20 kg/m , comprising administering to the patient a therapeutically effective amount of anamorelin or pharmaceutically acceptable salt thereof once daily for a therapeutically effective period of time.2) The method of claim 1 , further comprising increasing the total body mass of the patient.3) The method of claim 1 , further comprising increasing the total body mass claim 1 , lean body mass claim 1 , and fat mass of the patient.4) The method of claim 1 , further comprising improving the quality of life of the patient as measured by FAACT in the anorexia/cachexia domain.5) The method of claim 1 , wherein the therapeutically effective amount of anamorelin or pharmaceutically acceptable salt thereof comprises 100 mg of anamorelin hydrochloride based on the weight of the salt.6) A method of treating cachexia in a human cancer patient having a body weight loss greater than or equal to 2% in the previous 6 months and a body mass index less than 20 kg/m claim 1 , comprising administering to the patient a therapeutically effective amount of anamorelin or pharmaceutically acceptable salt thereof once daily for a therapeutically effective period of time and increasing total body mass of the patient.7) The method of claim 6 , comprising increasing the total body mass of the patient by 5% or more.8) The method of claim 6 , further comprising improving the quality of life of the patient as measured by FAACT in the anorexia/cachexia domain.9) The method of claim 6 , wherein the therapeutically effective amount of anamorelin or pharmaceutically acceptable salt thereof comprises 100 mg of anamorelin hydrochloride based on the weight of the salt.10) A method of treating cachexia in a human cancer patient having a body weight loss greater ...

METHODS AND COMPOSITIONS FOR IBOGAINE TREATMENT OF IMPULSE CONTROL DISORDER, ANXIETY-RELATED DISORDERS, VIOLENCE AND/OR ANGER, OR REGULATING FOOD INTAKE

This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and/or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof. 1. A method for treating an anxiety-related disorder in a patient in need thereof , comprising administering to the patient a therapeutically effective amount of ibogaine , ibogaine derivative , or a pharmaceutically acceptable salt and/or solvate thereof , wherein the patient is not addicted to cocaine or an opiate , and further wherein the therapeutically effective amount provides an efficacious average ibogaine serum level of between about 50 ng/mL and about 180 ng/mL while maintaining a QT interval of less than about 500 ms during said treatment.2. The method of claim 1 , wherein the anxiety-related disorder is selected from the group consisting of generalized anxiety disorder claim 1 , panic disorder claim 1 , obsessive-compulsive disorder claim 1 , and social anxiety disorder.3. A method for treating an impulse control disorder in a patient in need thereof claim 1 , comprising administering to the patient a therapeutically effective amount of ibogaine claim 1 , ibogaine derivative claim 1 , or a pharmaceutically acceptable salt and/or solvate thereof claim 1 , wherein the patient is not addicted to cocaine or an opiate claim 1 , and further wherein the therapeutically effective amount provides an efficacious average ibogaine serum level of between about 50 ng/mL and about 180 ng/mL while maintaining a QT interval of less than about 500 ms during said treatment.4. The method of claim 3 , wherein the impulse control disorder is selected from the group consisting of borderline personality disorder claim 3 , conduct disorder claim 3 , antisocial ...

HEATING AND HOT-WATER-SUPPLY APPARATUS

A heating and hot-water-supply apparatus is provided with: a control unit that performs control on the basis of detection parameters of a plurality of detection means installed at the aforementioned locations and a setting parameter set in an operation unit. The distribution means can adjust the distribution ratio so as to correspond to a heating operation, a hot-water supply operation, and the simultaneous heating and hot-water-supply operation. The control unit prohibits the simultaneous heating and hot-water-supply operation in a case in which the required heating capacity for the hot-water supply operation calculated on the basis of the detection parameters and the setting parameter is equal to or greater than a predetermined standard capacity. 1. A heating and hot-water-supply apparatus comprising:combustion means;a heat exchanger;a circulation passage which connects the heat exchanger and an external heating terminal;a circulation pump which is provided in the circulation passage;a bypass passage which branches from the circulation passage and bypasses the heating terminal;distribution means which is provided in a branch part between the circulation passage and the bypass passage;a heat exchanger for supplying hot water which is provided in the bypass passage;a water supply passage for supplying tap water to the heat exchanger for supplying hot water;a hot water supply passage for supplying hot water heated by the heat exchanger for supplying hot water at a predetermined hot water supply set temperature;a plurality of detection means;an operation part for performing a predetermined operation; anda control part for performing control based on setting parameters set by the operation part and detection parameters detected by the plurality of detection means,wherein the distribution means is configured such that a distribution ratio is adjustable so as to be adaptable to a heating operation, a hot water supply operation, and a simultaneous heating and hot-water- ...

BOILER CONTROL SYSTEM AND METHOD

The invention provides a boiler control system based on delayed cycle control, in which the control is implemented by interrupting a heating device enable signal (such as a BMS enable signal). This means the system can be used with electronic boilers without the boiler being aware (in terms of generating error codes) of the control taking place. 1. A boiler control system for controlling a heating device in a boiler , comprising:a delayed cycle controller for activating and deactivating said heating device based on an upper temperature threshold and a lower temperature threshold;a temperature sensor for measuring a boiler temperature;an interrupt unit for interrupting a heating device enable signal thereby to implement the delayed cycle control of the delayed cycle controller, wherein the heating device enable signal is a signal externally input to the boiler which takes priority over an internal thermostatic control of the heating device in the boiler.2. A system as claimed in claim 1 , wherein the interrupt unit comprises a relay switch.3. A system as claimed in claim 1 , wherein the delayed cycle controller is adapted to set the lower temperature threshold based on temperature measurements.4. A system as claimed in claim 1 , wherein the heating device enable signal comprises a building management system burner enable signal.6. A method as claimed in claim 5 , comprising performing a calibration operation to determine the upper temperature threshold.7. A method as claimed in claim 6 , wherein the calibration operation further comprises measuring a cooling time between pre-calibration internal upper and lower thermostat control settings.8. A method as claimed in claim 6 , wherein the upper temperature threshold is set equal to the pre-calibration internal upper temperature threshold claim 6 , and after the calibration the internal upper temperature threshold is increased.9. A method as claimed in claim 8 , wherein after the calibration the internal pre-calibration ...

Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens. 120.-. (canceled)21. A method of treating a male human with non-metastatic castration-resistant prostate cancer , the method comprising administering an anti-androgen at a dose of about 30 mg per day to about 480 mg per day to a male human in need of such treatment , wherein the anti-androgen is:4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2 fluoro-N-methylbenzamide,4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, or4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide;wherein said method further comprises administering a gonadotropin releasing hormone (GnRH) agonist.22. The method of claim 21 , wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer.23. The method of claim 21 , wherein the anti-androgen is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5 claim 21 ,7-diazaspiro [3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.24. The method of claim 23 , wherein 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5 claim 23 ,7-diazaspiro [3.4]oct-5-yl]-2-fluoro-N-methylbenzamide is administered daily to the male human.25. The method of claim 23 , wherein 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5 claim 23 ,7-diazaspiro [3 .4 ]oct-5-yl]-2-fluoro-N-methylbenzamide (ARN-509) is administered orally to the male human at a dose of about 180 mg per day to about 480 mg per day.26. The method of claim 23 , wherein 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5 claim 23 ,7-diazaspiro [3.4]oct-5-yl]-2-fluoro-N-methylbenzamide (ARN-509) is administered orally to the male human at a dose of:(a) about 30 mg per day;(b) about 60 mg per day;(c) about 90 mg per day;(d) about 120 mg per ...

METHODS TO TREAT ALLERGIC CONDITIONS

Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3. 1. A method to treat an allergic condition in a subject who has or is at risk of having an allergic condition , comprising administering to the subject a composition that inhibits Pim1 kinase.2. The method of claim 1 , wherein the allergic condition is selected from the group consisting of allergic rhinitis claim 1 , asthma claim 1 , airway hyperresponsiveness claim 1 , airway inflammation claim 1 , a food allergy claim 1 , eosinophilic esophagitis claim 1 , chronic urticaria claim 1 , atopic dermatitis claim 1 , occupational allergy claim 1 , allergic conjunctivitis claim 1 , hay fever claim 1 , airborne allergic sensitivities claim 1 , stinging insect allergy claim 1 , hypersensitivity pneumonitis claim 1 , eosinophilic lung diseases claim 1 , inflammatory bowel disease claim 1 , ulcerative colitis claim 1 , Crohn's disease and drug allergies.3. The method of claim 1 , wherein the allergic condition is asthma.4. The method of claim 1 , wherein the allergic condition is rhinitis.5. The method of claim 1 , wherein the allergic condition is a food allergy.6. The method of claim 5 , wherein the food allergy is a peanut allergy.7. The method of claim 1 , wherein the subject has been sensitized to an allergen and has been exposed to claim 1 , or is at risk of being exposed to claim 1 , the allergen.8. The method of claim 7 , wherein the allergen is selected from the group consisting of a food claim 7 , a plant claim 7 , a gas claim 7 , a pathogen claim 7 , a metal claim 7 , a glue and a drug.9. The method of claim 1 , wherein the composition comprises a compound selected from the group consisting of a small molecule inhibitor claim 1 , an antibody claim 1 , a chemical ...

Modulating Burner

A modulating burner apparatus includes a variable speed blower feeding a multi-chamber burner having first and second burner chambers. A manifold system communicates the blower with the burner, and a flow control valve member is located between the blower and the second chamber of the burner. The flow control valve is configured to provide fuel and air mixture from the blower to only the first burner chamber at lower blower speeds of the blower and to both the first and second burner chambers at higher blower speeds of the blower. 1. A modulating burner apparatus , comprising:one and only one source of pressurized pre-mixed fuel and air mixture, the source including at least one variable speed blower;a multi-chamber burner configured to burn the pre-mixed fuel and air mixture, the burner including at least a first burner chamber and a second burner chamber; anda flow controller configured to provide fuel and air mixture from the one and only one source to only the first burner chamber at lower blower speeds of the blower and to both the first and second burner chambers at higher blower speeds of the blower.2. The apparatus of claim 1 , wherein:the at least one variable speed blower includes one and only one blower.3. The apparatus of claim 1 , wherein:the at least one variable speed blower includes multiple blowers supplying a common source, the common source being the one and only one source.4. The apparatus of claim 1 , wherein the flow controller comprises:a valve member movable between a closed position blocking flow of fuel and air mixture to the second burner chamber, and an open position allowing flow of fuel and air mixture to the second burner chamber; anda biasing spring biasing the valve member toward the closed position.5. The apparatus of claim 4 , further comprising:a spring pre-load adjuster configured to adjust an opening force required to move the valve member from the closed position.6. The apparatus of claim 4 , wherein:the valve member is a disc ...

CD8+T-CELL SUBSETS AS MARKERS FOR PREDICTION OF DELAYED FRACTURE HEALING

The present invention relates to a method for diagnosis of delayed bone fracture healing, comprising determining the frequency of a subpopulation of CD8+ cells selected from a first group comprised of CD8+CD57+, CD8+CD28− and CD8+CD28−/CD57+, in a sample obtained from a subject. The present invention further relates to a system and a kit of parts for prediction and resulting options for preventing of delayed bone fracture healing. 1. A method for prognosis/prediction of delayed bone fracture healing , wherein said method comprises determining the frequency of a subpopulation of CD8+ cells selected from a first group comprised of CD8+CD57+ , CD8+CD28− and CD8+CD28−CD57+ , in a sample obtained from a subject.2. A method according to claim 1 , wherein said method further comprises determining the frequency of a subpopulation of CD8+ cells selected from a second group comprised of CD8+CD11a++ claim 1 , CD8+CD11a++CD28− claim 1 , CD8+CD11a++CD57+ and CD8+CD11a++CD28−CD57+ in said sample.3. A method according to claim 1 , wherein the sample is a blood sample.4. A method according to claim 1 , further comprising determining the frequency of a CD8+CD4+ subpopulation of CD3+ cells in said sample.5. A method according to claim 1 , further comprising determining the level of IL-6 in a sample of peripheral blood.6. A method according to claim 1 , further comprising determining of the Calori-Score of said subject.7. A method according to claim 1 , comprising comparing said frequency of a subpopulation of CD8+ cells claim 1 , said level of IL-6 or said Calori-Score to a standard.8. A method according to claim 1 , wherein a sample exhibiting a twofold higher frequency of CD8+CD4+ cells compared to a standard value determined for a large population of patients with normal fracture healing claim 1 , is assigned to a group having an elevated probability for delayed fracture healing.9. A method according to claim 1 , wherein a sample exhibiting a frequency of cells being CD11a++ claim ...

Bacteria preventive water holding tank construction for electric water heaters

A water holding tank for electric water heaters is described and particularly an improvement to the bottom end construction of the tank to prevent bacteria proliferation and the elimination of the cavitated circumferential area where sediments deposit to form a culture bed for bacteria to proliferate. Instead of modifying the shape of the bottom wall the improvement is a simple solution in that a filler material is set in at least a lowermost portion, and preferably a major portion, of the cavitated circumferential area to isolate that area from the interior of the water holding tank and form smooth flat surface areas which are planar to cause sediments to disperse and not form beds for bacteria to proliferate. 1. An electric water heater comprising a water holding tank having a cylindrical side wall , a top wall and a dome-shaped bottom wall; a hot water conduit for extracting hot water from an upper portion of said tank , a cold water inlet for releasing water under pressure in a lower portion of said tank , two or more resistive heating elements to heat water in said upper and a lower portion of said tank , temperature sensing and control means to operate said resistive heating elements to heat water within said tank portions to a pre-set desired temperature , a cavitated circumferential area defined between a lower end section of said tank cylindrical side wall and said dome-shaped bottom wall , and a filler material filling at least a lowermost portion of said cavitated circumferential area to isolate said at least lowermost portion of said cavitated circumferential area from said lower portion of said tank.2. The electric water heater as claimed in wherein a drain outlet is disposed in said cylindrical side wall slightly above an upper surface of said filler material claim 1 , said drain outlet having a closure means.3. The electric water heater as claimed in wherein said filler material is one of a polymer and a cement hard settable material.4. The electric ...

THERAPEUTIC AGENTS FOR OCULAR INFLAMMATORY DISEASE COMPRISING INTERLEUKIN 6 RECEPTOR INHIBITOR AS ACTIVE INGREDIENT

The present invention relates to therapeutic and/or prophylactic agents for ocular inflammatory disease, which comprise an interleukin 6 (IL-6) receptor inhibitor as an active ingredient. 112-. (canceled)13. A method for treating ocular inflammatory disease , comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of an anti-interleukin 6 (IL-6) receptor inhibitor.14. The method according to claim 13 , wherein the pharmaceutical composition is administered by parenteral administration.15. The method according to claim 13 , wherein the anti-interleukin 6 (IL-6) receptor inhibitor is an anti-IL-6 receptor antibody or an anti-IL-6 antibody.16. The method according to claim 13 , wherein the ocular inflammatory disease is any of panuveitis claim 13 , anterior uveitis claim 13 , intermediate uveitis claim 13 , scleritis claim 13 , keratitis claim 13 , orbital inflammation claim 13 , optic neuritis claim 13 , dry eye claim 13 , diabetic retinopathy claim 13 , proliferative vitreoretinopathy or postoperative inflammation.17. The method according to claim 15 , wherein the anti-interleukin 6 (IL-6) receptor antibody is a chimeric antibody claim 15 , a humanized antibody or a human antibody.18. The method according to claim 15 , wherein the anti-interleukin 6 (IL-6) receptor antibody is selected from the group consisting of humanized PM-1 antibody claim 15 , MR16-1 antibody claim 15 , AUK12-20 antibody claim 15 , AUK64-7 antibody claim 15 , and AUK146-15 antibody.19. The method according to claim 13 , wherein the anti-interleukin 6 (IL-6) receptor inhibitor is administered at a dose of 0.01 to 100 mg/kg body weight. This application is a Continuation of U.S. application Ser. No. 15/221,948, filed Jul. 28, 2016, which is a Continuation of U.S. application Ser. No. 12/452,827, which is the U.S. National Stage application of PCT/JP2008/063809, filed Jul. 25, 2008, which claims priority from Japanese application JP 2007- ...

HOT WATER SUPPLY SYSTEM

The present invention achieves energy saving and a decrease in facility cost for a hot water supply device by dividing a water receiving tank. A hot water supply system comprising: a water receiving tank receiving water supplied from a water supply source; a hot water storage tank connected to the water receiving tank via a connection pipe and storing hot water and supplying hot water to a hot water supply load; and a hot water supply device supplying the water stored in the hot water storage tank. The water receiving tank including: a temperature non-raising water receiving tank storing water supplied from the water supply source, the temperature non-raising water receiving tank, a general water supply pipe performing general water supply being connected; a temperature raising water receiving tank storing the water supplied from the water supply source and supplying the stored water to the hot water storage tank; and a preheating device preheating the water stored in the temperature raising water receiving tank. 1. A hot water supply system comprising:a water receiving tank receiving water supplied from a water supply source;a hot water storage tank connected to the water receiving tank via a connection pipe and storing hot water, and supplying hot water to a hot water supply load; anda hot water supply device supplying the water stored in the hot water storage tank,the water receiving tank including:a temperature non-raising water receiving tank storing water supplied from the water supply source, the temperature non-raising water receiving tank being connected with a general water supply pipe performing general water supply;a temperature raising water receiving tank storing the water supplied from the water supply source and supplying the stored water to the hot water storage tank; anda preheating device preheating the water stored in the temperature raising water receiving tank.2. The hot water supply system of claim 1 , wherein a capacity of the temperature non ...

DIGITAL FLUID HEATING SYSTEM

A digital fluid heating system may include a solar collection system configured for focusing sunlight on a focal axis, an elongated flow element arranged and configured for transporting fluid along the solar collection system at the focal axis, and a flow-control assembly comprising a digitally controlled valve configured to control the flow of the fluid in the elongated flow element such that pathogens present in the fluid are substantially inactivated before the fluid exits the fluid heating system and at a maximized flow rate under the given energy providing conditions. The system may also include one or more digital controls and communication systems for remote and/or automatic control. 1. A digital fluid heating system , comprising:a solar collection system configured for focusing sunlight on a focal axis;an elongated flow element arranged and configured for transporting fluid along the solar collection system at the focal axis; anda flow-control assembly comprising a digitally controlled valve configured to control the flow of the fluid in the elongated flow element such that pathogens present in the fluid are substantially inactivated before the fluid exits the fluid heating system and at a maximized flow rate under the given energy providing conditions.2. The fluid heating system of claim 1 , further comprising a preheat heat exchanger configured to utilize fluid exiting the fluid heating system to heat fluid entering the fluid heating system.3. The fluid heating system of claim 2 , wherein the preheat heat exchanger comprises a first tortuous pathway and a second tortuous pathway claim 2 , the first and second tortuous pathways being in substantial alignment with one another such that heat may be exchanged between the pathways.4. The fluid heating system of claim 1 , further comprising a water collecting reservoir configured to collect water to be pasteurized.5. The fluid heating system of claim 1 , further comprising a reservoir sensor configured to sense ...

CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS

The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy. 1. A method of treating patients suffering from multiple sclerosis and who are refractory to at least one conventional therapy for multiple sclerosis comprising administering Cladribine in combination with IFN-β , wherein Cladribine is to be orally administered following the sequential steps below:(i) an induction period wherein Cladribine is administered and wherein the total dose of Cladribine reached at the end of the induction period is from about 1.5 mg/kg to about 3.5 mg/kg;(ii) a Cladribine-free period wherein no Cladribine is administered;(iii) a maintenance period wherein Cladribine is administered and wherein the total dose of Cladribine administered during the maintenance period is lower than or equal to the total dose of Cladribine reached at the end of the induction period (i); and(iv) a Cladribine-free period wherein no Cladribine is administered.2. A pharmaceutical composition comprising Cladribine and one or more pharmaceutically acceptable ingredient.3. The pharmaceutical composition according to claim 2 , wherein said composition is a tablet claim 2 , capsule claim 2 , oral suspension or syrup and comprises between 3 and 500 mg Cladribine.4. The pharmaceutical composition according to claim 3 , said composition further comprising interferon beta or interferon beta 1a.53. A method of treating patients suffering from multiple sclerosis and who are refractory to at least one conventional therapy for multiple sclerosis comprising administering Cladribine in combination with IFN- to a patient suffering from multiple sclerosis and who are refractory to at least one conventional therapy for multiple sclerosis in an amount effective to obtain a beneficial result claim 3 , wherein Cladribine is to be orally administered following the sequential ...

METHODS AND DEVICES FOR LOCALIZING COMPOSITIONS

Methods for localizing a composition to a treatment site, which includes placing at least two electrodes against a skin surface where dissipation of the composition is to be limited, wherein the at least two electrodes do not penetrate the skin surface; subcutaneously or intramuscularly injecting the composition, which has a net negative or net positive charge at physiological pH, between the at least two electrodes or underneath one of the at least two electrodes; and applying a positive charge to one of the at least two electrodes and a negative charge to another of the at least two electrodes to produce a directional electric field that limits dissipation of the injected composition. 1. A method for localizing a composition to a treatment site , the method comprising:a) placing at least two electrodes against a skin surface where dissipation of the composition is to be limited, wherein the at least two electrodes do not penetrate the skin surface;b) subcutaneously or intramuscularly injecting the composition between the at least two electrodes or underneath one of the at least two electrodes, wherein the composition comprises a net negative or net positive charge at physiological pH; andc) applying a positive charge to one of the at least two electrodes and a negative charge to another of the at least two electrodes to produce a directional electric field that limits dissipation of the injected composition.2. The method of claim 1 , wherein the composition comprises a neurotoxin.3. The method of claim 2 , wherein the neurotoxin comprises a Clostridial toxin.4. The method of claim 3 , wherein the neurotoxin comprises a native botulinum toxin.5. The method of claim 4 , wherein the botulinum toxin is selected from the group consisting of a native BoNT/A claim 4 , a native BoNT/E claim 4 , and a native BoNT/B.6. The method of claim 2 , wherein the neurotoxin comprises a recombinant botulinum toxin.7. The method of claim 6 , wherein the recombinant botulinum toxin is ...

MEDICAL TREATMENTS BASED ON ANAMORELIN

Methods of treating cancer related conditions using anamorelin are described. 123-. (canceled)24. A method of treating cancer associated weight loss in a patient in need thereof comprising administering to said patient a therapeutically effective amount of anamorelin or a pharmaceutically acceptable salt thereof , wherein:{'sup': '2', 'a. said patient has a body mass index of <20 kg/m; and'}b. said patient has involuntary weight loss of >2% during the previous 6 months.251. The method of claim , wherein said patient has an ECOG score of 0 , 1 , or 2.261. The method of claim , further for treating anorexia symptoms in said patient , wherein said patient has low quality of life as measured by FAACT in the anorexia/cachexia domain.271. The method of claim , further for treating anorexia symptoms in said patient , wherein:a. said patient has low quality of life as measured by FAACT in the anorexia/cachexia domain; andb. said patient has low physical and functional well-being as measured by FAACT in the anorexia/cachexia domain.28. The method of claim 24 , wherein said patient has stage III unresectable or stage IV NSCLC.29. The method of claim 24 , wherein said therapeutically effective amount comprises 100 mg of anamorelin or a pharmaceutically acceptable salt thereof once daily.30. The method of claim 24 , wherein said therapeutically effective amount comprises 100 mg of anamorelin HCl based on the weight of the salt administered once daily.31. The method of claim 26 , wherein said method increases the body weight of said patient and improves anorexia symptoms as measured by FAACT in the anorexia/cachexia domain.32. The method of claim 27 , wherein said method increases the body weight of said patient and improves physical and functional well-being as measured by FAACT in the anorexia/cachexia domain.33. The method of claim 27 , wherein said method increases the body weight of said patient claim 27 , improves physical and functional well-being as measured by FAACT in ...

MULTI-TEMPERATURE OUTPUT FLUID HEATING SYSTEM

A multi-temperature output fluid heating system including an input for receiving a fluid supply, a single heating source, a first output, a second output and a bypass path. The first output is fluidly connected to the input, where the first output is adapted for control by a first control device and to receive heat from the single heating source to achieve a first temperature at the first output. The bypass path fluidly connects the input and the second output. The input is adapted to empty a first portion of the fluid supply into the first output and a second portion of the input into the bypass path. The second output is adapted to receive an output from the first output and an output from the bypass path to achieve a second temperature. 1. A multi-temperature output fluid heating system comprising:(a) an input for receiving a fluid supply;(b) a single heating source;(c) a first output fluidly connected to said input, wherein said first output is adapted for control by a first control device and to receive heat from said single heating source to achieve a first temperature at said first output;(d) a second output; and(e) a bypass path fluidly connecting said input and said second output,whereby said input is adapted to empty a first portion of the fluid supply into said first output and a second portion of said fluid supply into said bypass path and said second output is adapted to receive an output from said first output and an output from said bypass path to achieve a second temperature.2. The multi-temperature output fluid heating system of claim 1 , further comprising a pump disposed upstream of said first output and configured for pushing an output of said first output through a heat exchanger.3. The multi-temperature output fluid heating system of claim 2 , wherein said heat exchanger is a plate-type heat exchanger.4. The multi-temperature output fluid heating system of claim 1 , wherein said first control device is a modulating device configured to modulate ...

CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS

The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy. 1. A method of treating patients suffering from multiple sclerosis and who are refractory to at least one conventional therapy for multiple sclerosis comprising administering IFN-β in combination with cladrabine , wherein Cladribine is orally administered following the sequential steps below:(i) An induction period wherein Cladribine is administered and wherein the total dose of Cladribine reached at the end of the induction period is from about 1.7 mg/kg to about 3.5 mg/kg;(ii) A Cladribine-free period wherein no Cladribine is administered;(iii) A maintenance period wherein Cladribine is administered and wherein the total dose of Cladribine administered during the maintenance period is lower than or equal to the total dose of Cladribine reached at the end of the induction period (i); and(iv) A Cladribine-free period wherein no Cladribine is administered.2. The method of claim 1 , wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is about 1 year.3. The method of claim 2 , wherein the duration of the induction period is about 4 months and the duration of the Cladribine-free period (ii) is about 8 months claim 2 , or the duration of the induction period is about 2 months and the duration of the Cladribine-free period (ii) is about 10 months.4. The method of claim 2 , wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is about 1 year (about 12 months) and the total dose of Cladribine reached at the end of this year of treatment is about 1.7 mg/kg or about 3.5 mg/kg.5. The method of claim 1 , wherein the combined duration of the maintenance period (iii) with the Cladribine-free period (iv) is about 1 year.6. The method of claim 5 , wherein the duration of the maintenance ...

Sol-Gel Phase-Reversible Hydrogel Templates and Uses Thereof

Discrete microstructures of predefined size and shape are prepared using sol-gel phase-reversible hydrogel templates. An aqueous solution of hydrogel-forming material is covered onto a microfabricated silicon wafer master template having predefined microfeatures, such as pillars. A hydrogel template is formed, usually by lowering the temperature, and the formed hydrogel template is peeled away from the silicon master template. The wells of predefined size and shape on the hydrogel template are filled with a solution or a paste of a water-insoluble polymer, and the solvent is removed to form solid structures. The formed microstructures are released from the hydrogel template by simply melting the hydrogel template in water. The microstructures are collected by centrifugation. The microstructures fabricated by this method exhibit pre-defined size and shape that exactly correspond to the microwells of the hydrogel template. The method of preparing microstructures based on hydrogel templates is simple and can easily produce large quantities of the microstructures. 133.-. (canceled)34. A method of making drug-containing microparticles comprising:(a) filling a plurality of wells provided in a preformed, dissolvable hydrogel mold with a non-aqueous composition comprising: at least one drug, a non-water soluble, biodegradable polymer and non-aqueous solvent, which dissolvable hydrogel mold is formed of a sol-gel phase reversible hydrogel;(b) solidifying the composition in the plurality of wells by evaporating the non-aqueous solvent, thereby forming microparticles; and(c) harvesting the microparticles from the preformed dissolvable hydrogel mold by dissolving the hydrogel mold in an aqueous solution.35. The method of claim 34 , wherein the drug is present in the microparticles in the range of about 1-80% by weight.36. The method of claim 34 , wherein the drug is present in the microparticles in the range of about 5-50% by weight.37. The method of claim 34 , wherein the ...

METHOD AND APPARATUS FOR COMBINED HEAT AND POWER GENERATION

A temperature control apparatus for a building, the apparatus comprising: an electricity generator, operable to contribute to an electrical power supply for consumer appliances at the building; a heat transfer circuit adapted to circulate heat transfer fluid to cool the electricity generator; a heating system comprising a heat source for providing heat energy to a space heater for heating at least one zone of the building and to a hot water tank arranged to store a supply of hot water for the building, and a heat exchanger adapted to supplement the heat energy from the heat source with heat energy obtained from the heat transfer circuit; a user interface adapted to enable a user to select at least one of (a) a desired temperature for the at least one zone of the building, and a first time period during which the desired temperature is to be maintained; and (b) a second time period for the supply of hot water from the hot water tank; and the apparatus further comprising: a controller configured to determine when to operate the electricity generator based on at least one of: (i) the thermal capacity of the hot water tank; and (ii) the first time period, the desired temperature and the current temperature of the at least one zone of the building. 2. The apparatus of wherein the controller is configured to operate both the electricity generator and the heat source prior to the first time period claim 1 , to achieve the desired temperature in the at least one zone of the building at the start of the first time period.3. The apparatus of or in which the controller is configured to operate the electricity generator to generate electricity during a preheat phase to preheat at least a part of the space heater before switching on the heat source.5. The apparatus of wherein the heat source is configured to provide heat to a hot water tank arranged to store a supply of hot water for the building claim 4 , and the controller is configured to determine when to operate the ...

MULTI-TEMPERATURE OUTPUT FLUID HEATING SYSTEM

A multi-temperature output fluid heating system including an input for receiving a fluid supply, a single heating source, a first output, a second output and a bypass path. The first output is fluidly connected to the input, where the first output is adapted for control by a first control device and to receive heat from the single heating source to achieve a first temperature at the first output. The bypass path fluidly connects the input and the second output. The input is adapted to empty a first portion of the fluid supply into the first output and a second portion of the input into the bypass path. The second output is adapted to receive an output from the first output and an output from the bypass path to achieve a second temperature. 1. A method of adjusting the target temperature of a fluid heating system , said method comprising:(a) obtaining a log of at least one event over a period of time;(b) calculating a parameter of said at least one event over said period of time from said log;(c) comparing said parameter to a pre-determined threshold, wherein if said parameter exceeds said pre-determined threshold, a difference between the parameter and said pre-determined threshold is calculated; and(d) applying said difference to the target temperature of the fluid heating system.2. The method of claim 1 , wherein said parameter is frequency.3. The method of claim 1 , wherein the fluid heating system comprises a space heating loop having a supply line and a return line and said parameter is the temperature of the return line.4. The method of claim 1 , said event is selected from the group consisting of turn-on-off of the fluid heating system claim 1 , turn-on of the fluid heating system claim 1 , turn-off of the fluid heating system and duration of turn-on of the fluid heating system. This divisional application claims the benefit of priority from non-provisional application U.S. Ser. No. 14/602,248 filed on Jan. 21, 2015 and provisional application U.S. Ser. No. ...

METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)

The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.

Cancer Stem Cell-Targeted Cancer Therapy

The present invention provides methods for stabilizing, reducing or eliminating cancer cells. In particular, the present invention provides prophylactically and/or therapeutically effective regimens for the prevention, treatment and/or management of cancer, the regimens comprising administering one or more cancer therapies to a subject to reduce a cancer cell population. The therapy(ies) in the prophylactically and/or therapeutically effective regimen can be administered at a lower dose than currently used or known to one of skill in the art and/or for a longer period of time and/or more frequently than currently administered or known to one of skill in the art. 1. A method for preventing , treating , or managing cancer , the method comprising administering to a human subject in need thereof a prophylactically or therapeutically effective regimen , the regimen comprising the administration of a proliferation based therapy to the human subject , wherein the regimen results in at least an approximately 10% reduction in cancer cells , wherein the proliferation based therapy comprises the administration of an immunotherapeutic.2. The method of claim 1 , wherein the regimen results in an approximately 25% reduction claim 1 , an approximately 40% reduction claim 1 , an approximately 50% reduction or an approximately 75% reduction in the cancer cells.3. The method of claim 1 , wherein the reduction in the cancer cells is determined by comparing the amount of cells with a cancer cell marker phenotype present in a tissue sample from the human subject to the amount of cells with the same cancer cell marker phenotype present in a tissue sample from the same human subject at an earlier time point.4. The method of claim 1 , wherein the regimen further comprises monitoring the cancer cells in the human subject.5. The method of claim 1 , wherein the regimen further comprises monitoring cancer stem cells in the human subject.6. The method of claim 4 , wherein the monitoring ...

Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens. 120-. (canceled)21. A method of treating non-metastatic castration-resistant prostate cancer in a male human comprising administering an anti-androgen to a male human in need of such treatment at a dose of about 30 mg per day to about 480 mg per day , wherein the anti-androgen is administered in combination with a gonadotropin-releasing hormone (GnRH) agonist or orchiectomy.22. The method of claim 21 , wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer.23. The method of claim 21 , wherein the anti-androgen is a first-generation anti-androgen.24. The method of claim 21 , wherein the anti-androgen is a second-generation anti-androgen.25. The method of claim 21 , wherein the anti-androgen is an androgen receptor (AR) antagonist.26. The method of claim 21 , wherein the anti-androgen is an androgen receptor (AR) antagonist and the AR antagonist is a full AR antagonist.27. The method of claim 21 , wherein the anti-androgen is an androgen receptor (AR) antagonist and the AR antagonist is a partial AR antagonist.28. The method of claim 21 , wherein the anti-androgen is administered in combination with the GnRH agonist.29. The method of claim 21 , wherein the anti-androgen is administered in combination with the GnRH agonist and the GnRH agonist is leuprolide claim 21 , buserelin claim 21 , nafarelin claim 21 , histrelin claim 21 , goserelin claim 21 , or deslorelin.30. The method of claim 21 , wherein the anti-androgen is administered post-orchiectomy.31. The method of claim 21 , wherein the male human previously received a first-generation anti-androgen claim 21 , and wherein the first-generation anti-androgen is bicalutamide claim 21 , flutamide or nilutamide.32. The method of claim 21 , wherein the anti-androgen is administered daily to the male human.33. The method of claim 21 , ...

Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens. 120-. (canceled)21. A method of treating non-metastatic castration-resistant prostate cancer in a male human comprising administering a therapeutically effective amount of an anti-androgen to a male human in need of such treatment , wherein the anti-androgen is 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5 ,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide.22. The method of claim 21 , wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer.23. The method of claim 22 , wherein the male human with the high risk non-metastatic castration-resistant prostate cancer has a prostate-specific antigen doubling time (PSADT) that is less than or equal to 10 months.24. The method of claim 21 , wherein administration of the anti-androgen provides an increase in the metastasis-free survival of the male human claim 21 , relative to the mean survival rate of a population of male humans claim 21 , with the non-metastatic castration-resistant prostate cancer claim 21 , said population having been treated with a placebo.25. The method of that provides an increase in the metastasis-free survival of the male human with prostate cancer claim 21 , relative to the mean survival rate of a population of male humans with prostate cancer claim 21 , said population having been treated with a placebo.26. The method of claim 21 , wherein the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5 claim 21 ,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide is administered daily to the male human.27. The method of claim 21 , wherein the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5 claim 21 ,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide is administered orally to the male human.28. The method of claim 21 , wherein the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5 claim 21 ...

MEDICAL TREATMENTS BASED ON ANAMORELIN

Methods of treating cancer related conditions using anamorelin are described. 123-. (canceled)24. A method of treating weight loss in a human cancer patient comprising administering to said patient 100 mg of anamorelin or a pharmaceutically acceptable salt thereof once daily for a therapeutically effective period of time.25. A method of treating early satiety in a human cancer patient comprising administering to said patient 100 mg of anamorelin or a pharmaceutically acceptable salt thereof once daily for a therapeutically effective period of time.26. A method of improving quality of life as measured by FAACT in the anorexia/cachexia domain in a human cancer patient comprising administering to said patient 100 mg of anamorelin or a pharmaceutically acceptable salt thereof once daily for a therapeutically effective period of time.27. A method of increasing total body mass , lean body mass , and fat mass in a human cancer patient comprising administering to said patient 100 mg of anamorelin or a pharmaceutically acceptable salt thereof once daily for a therapeutically effective period of time.28. The method of claim 24 , wherein said patient has a BMI less than 20 kg/m.29. The method of claim 24 , wherein said patient has a BMI less than 20 kg/mand a body weight loss greater than 2% in the previous 6 months.30. The method of claim 24 , wherein said patient has a performance status on the ECOG scale of 2 or higher.31. The method of claim 24 , wherein said therapeutically effective amount of anamorelin comprises 100 mg of anamorelin HCl based on the weight of the salt administered orally once daily at least one hour before the first meal.32. The method of claim 24 , wherein said therapeutically effective period of time is twelve weeks.33. The method of claim 24 , wherein the method further treats early satiety.34. The method of claim 24 , wherein the method further improves quality of life as measured by FAACT in the anorexia/cachexia domain.35. The method of claim 24 , ...

CYTOTOXIC T CELL RESPONSE MODIFIERS

The present invention relates to a compound selectively binding to a sensory receptor or selectively altering the expression of a sensory receptor for use in a method for treating or preventing a disease associated with a pathologic cellular cytotoxic T cell (CTL) response. Further, the invention relates to means for detecting a sensory receptor for use in a method for diagnosing cellular resistance against CTL response in a patient. The invention further embraces a method for determining the resistance of a cell against a CTL response in vitro and to a method for identifying agents that influence the response of cells to CTLs. 115.-. (canceled)16. A method for treating or preventing a disease associated with a pathologic cellular cytotoxic T cell (CTL) response in a subject , preferably a disease selected from the group consisting of neoplasia , in particular cancer , an autoimmune disease , an infection and graft-versus-host disease , the method comprising the step of administering to the subject at least one compound selectively binding to at least one sensory receptor or selectively altering the expression or activity of a sensory receptor or selectively altering the expression or activity of a polypeptide involved in cell signaling of a sensory receptor.17. The method according to claim 16 , wherein said sensory receptor: (i) regulates or mediates CTL response; and/or (ii) functions as an immune-checkpoint molecule.18. The method according to claim 16 , wherein the sensory receptor is a receptor localized at the cellular surface claim 16 , preferably wherein said sensory receptor is selected from the group consisting of (i) a taste receptor, in particular a taste receptor type 2 (TAS2R), in particular taste receptor type 2 member 3 (TAS2R3),', '(ii) an olfactory receptor of family 1, 2 or 51, in particular an olfactory receptor of family 1 subfamily F (OR1F), in particular an olfactory receptor of family 1 subfamily F member 1 (OR1F1), an olfactory receptor of ...

Methods For Treating Cancers Using Ace Inhibitors, ARB, or Celecoxib and Olmesartan

Methods for treating cancers, such as breast cancer or skin cancer, using an ACE or ARB, or a combination of celecoxib and olmesartan. 1. A method of treating cancer , comprising administering a therapeutically effective amount of olmesartan or a pharmaceutically acceptable salt thereof , and celecoxib or a pharmaceutically acceptable salt thereof , to a subject in need thereof.2. A method of treating breast cancer , skin cancer , or glioblastoma , comprising administering a therapeutically effective amount of olmesartan or a pharmaceutically acceptable salt thereof , and celecoxib or a pharmaceutically acceptable salt thereof , to a subject in need thereof.3. (canceled)4. (canceled)5. The method of claim 2 , wherein the olmesartan and celecoxib are administered concurrently as a pharmaceutical composition.6. The method of claim 2 , wherein administering the therapeutically effective amount of olmesartan and celecoxib comprises administering a fixed dose combination comprising olmesartan and celecoxib.7. The method of claim 2 , wherein olmesartan and celecoxib are administered orally.8. The method of claim 2 , wherein the subject is human.9. A method of treating a cancer characterized by abnormal activation of COX-2 claim 2 , comprising administering a therapeutically effective amount of olmesartan or a pharmaceutically acceptable salt thereof claim 2 , and celecoxib or a pharmaceutically acceptable salt thereof claim 2 , to a subject in need thereof.10. The method of claim 9 , wherein the olmesartan and celecoxib are administered concurrently as a pharmaceutical composition.11. The method of claim 9 , wherein administering the therapeutically effective amount of olmesartan and celecoxib comprises administering a fixed dose combination comprising olmesartan and celecoxib.12. The method of claim 9 , wherein olmesartan and celecoxib are administered orally.13. The method of claim 9 , wherein olmesartan and celecoxib are administered intravenously.14. The method of ...

Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens. 120.-. (canceled)21. A method of treating non-metastatic castration-resistant prostate cancer in a male human comprising administering an anti-androgen at a dose of about 30 mg per day to about 480 mg per day to a male human in need of such treatment , wherein the anti-androgen is:4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2fluoro-N-methylbenzamide,4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, or4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide;wherein the anti-androgen is used in combination with orchiectomy.22. The method of claim 21 , wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer.23. The method of claim 21 , wherein the anti-androgen is administered orally to the male human.24. The method of claim 21 , wherein said method further comprises administering a gonadotropin releasing hormone (GnRH) agonist.25. The method of claim 24 , wherein the GnRH agonist is leuprolide claim 24 , buserelin claim 24 , naferelin claim 24 , histrelin claim 24 , goserelin or deslorelin.26. The method of claim 21 , wherein the anti-androgen is administered post orchiectomy.27. The method of claim 21 , wherein the anti-androgen is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5 claim 21 ,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.28. The method of claim 27 , wherein 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5 claim 27 ,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide is administered daily to the male human.29. The method of claim 27 , wherein 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5 claim 27 ,7-diazaspiro[3.4 ]oct-5-yl]-2-fluoro-N-methylbenzamide is ...

METHOD OF TREATMENT OF AGGRESSION

The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity. 1. A method of treating impulsive aggression in a post-traumatic stress disorder (PTSD) patient , comprising:administering 10 mg/day to 200 mg/day of molindone to a patient with PTSD as the sole condition and manifesting impulsive aggression not controlled by PTSD treatment.2. The method of claim 1 , wherein 15 to 120 mg/day of molindone is administered.3. The method of claim 1 , wherein the administration decreases side effects associated with molindone.4. The method of claim 4 , wherein the side effects are selected from drowsiness claim 4 , depression claim 4 , hyperactivity claim 4 , euphoria claim 4 , extrapyramidal reactions claim 4 , akathisia claim 4 , akinesia claim 4 , dystonic syndrome claim 4 , tardive dyskinesia claim 4 , tachycardia claim 4 , nausea claim 4 , dry mouth claim 4 , urinary retention claim 4 , and constipation.5. The method of claim 1 , wherein the administration results in reduction of undesirable behavior and intolerable side effects.6. The method of claim 1 , wherein the patient is a child or an adult. This application is a Continuation of U.S. application Ser. No. 15/782,334, filed Oct. 12, 2017, which is a Continuation of U.S. patent application Ser. No. 13/951,642, filed Jul. 26, 2013, which is a Continuation of U.S. application Ser. No. 12/654,455, filed Dec. 18, 2009, which claims priority from U.S. Provisional Application No. 61/193,735, filed Dec. 19, 2008, the entire contents of which are incorporated herein by reference.Aggression and similar syndromes, including impulsivity and irritability, represent a broad category of behaviors that complicate the management of several disease states, such as attention deficit hyperactivity disorder (ADHD), bipolar disorder, autism, and post traumatic stress disorder. In some cases, ...

APPARATUS FOR REMOVING RESIDUAL WATER IN HOT WATER MAT USING CIRCULATING PUMP

Provided is an apparatus for removing residual water in a hot water mat using a circulating pump, in which residual water that remains in a boiler and a mat of the hot water mat and a mat can be conveniently and rapidly removed, the configuration of the apparatus for removing residual water in the hot water mat can be simplified and the leakage at a connector of the boiler and the mat is prevented from occurring so that the risk of suffering a low-temperature burn can be eliminated during the removal of residual water. The apparatus for removing residual water in a hot water mat, the hot water mat including a boiler () for supplying hot water by heating water and a mat () in which heating is performed by using hot water heated by the boiler () as a heat source, includes: a circulating pump () provided in the boiler () and configured to pump water to be circulated between the boiler () and the mat (); a boiler connector () including a boiler-side discharge connector () and boiler-side water return connectors ( ), which are connected to the boiler (); a mat connector () including a mat-side discharge connector () and mat-side water return connectors (), which are connected to the mat (); and a residual water removing connector () coupled between the boiler connector () and the mat connector () and including a residual water outlet () through which water flowing through the boiler-side discharge connector () is discharged. 1100200100. An apparatus for removing residual water in a hot water mat , the hot water mat including a boiler () configured to supply hot water by heating water and a mat () in which heating is performed by using hot water heated by the boiler () as a heat source , the apparatus comprising:{'b': 120', '100', '100', '200, 'a circulating pump () provided in the boiler () and configured to pump water to be circulated between the boiler () and the mat ();'}{'b': 140', '141', '142', '143', '100, 'a boiler connector () including a boiler-side discharge ...

Burner with Adjustable End Cap and Method of Operating Same

A boiler system comprises a housing with a generally cylindrical shape extends between first and second walls to provide a generally cylindrical space. A fire tube is positioned near a bottom of the generally cylindrical housing and extends longitudinally from a first wall of the cylindrical housing to a fire tube end wall. The boiler system also includes a burner with a generally cylindrical housing which defines a generally cylindrical chamber and an end plate. The burner extends into the fire tube, and the fire tube provides a combustion chamber where combustion of an air-fuel mixture is accomplished using the burner. The end plate of the burner is adjustable so as to adjust the flame that extends from within the burner housing into the fire tube. 1. A boiler system comprising:a housing having a generally cylindrical shape and extending between first and second walls to provide a generally cylindrical space;a fire tube positioned near a bottom of the generally cylindrical housing and extending longitudinally from a first wall of the cylindrical housing to a fire tube end wall,a burner having a generally cylindrical housing and an end plate, the housing defining a generally cylindrical chamber;wherein the fire tube provides a combustion chamber where combustion of an air-fuel mixture is accomplished using the burner, the burner extending into the fire tube; andwherein the end plate of the burner is adjustable between a minimum gap position corresponding to and providing a minimum gap generally located between an end of the cylindrical housing of the burner and a surface of the end plate facing the end of the cylindrical housing, and a predefined position corresponding to and providing a gap between the end of the cylindrical housing of the burner and the surface of the end plate facing the end of the cylindrical housing, such that the gap of the predefined position is larger than the minimum gap, so as to adjust a flame that extends from within the burner housing ...

NON-INVASIVE METHOD FOR ASSESSING LIVER FIBROSIS PROGRESSION

A method for implementing an adapted patient care for an individual suffering from liver fibrosis after assessing liver fibrosis progression in the individual, and thus determining whether the individual is a slow, medium or fast fibroser. Also, a method for treating an individual suffering from liver fibrosis and identified as a fast fibroser, which includes the steps of identifying the individual as a fast fibroser by assessing fibrosis progression and treating the individual by administering without delay at least one therapeutic agent for treating liver fibrosis, or for treating the underlying cause responsible for liver fibrosis, or both. 1. A method for treating an individual suffering from liver fibrosis comprising: measuring at least three markers in an individual, wherein said markers are measured in a blood sample obtained from the individual and are selected from the group consisting of α-2 macroglobulin, hyaluronic acid, gamma-glutamyl transpeptidase, bilirubin, platelet count, prothrombin index, aspartate amino-transferase, alanine amino-transferase, urea, glycemia, and ferritin; and/or said markers are clinical markers selected from weight, age and sex; and', 'combining said at least four measured markers in a logistic or linear regression function, thereby determining a fibrosis level in the individual;, 'assessing the fibrosis progression in said individual to determine whether said individual is a slow fibroser, a medium fibroser or a fast fibroser, by'}calculating a ratio of said fibrosis level to cause duration, thereby obtaining a value-useful for assessing the liver fibrosis progression in the individual; andimplementing an adapted patient care depending on whether the subject is a slow fibroser, a medium fibroser or a fast fibroser.2. The method of claim 1 , wherein fibrosis progression is assessed by measuring at two different times t1 and t2 the fibrosis levels FL(t1) and FL(t2); and calculating a ratio FL(t2)−FL(t1) to cause duration claim 1 ...

Cancer Stem Cell-Targeted Cancer Therapy

The present invention provides methods for stabilizing, reducing or eliminating cancer cells. In particular, the present invention provides prophylactically and/or therapeutically effective regimens for the prevention, treatment and/or management of cancer, the regimens comprising administering one or more cancer therapies to a subject to reduce a cancer cell population. The therapy(ies) in the prophylactically and/or therapeutically effective regimen can be administered at a lower dose than currently used or known to one of skill in the art and/or for a longer period of time and/or more frequently than currently administered or known to one of skill in the art. 1. A method for preventing , treating , or managing cancer , the method comprising administering to a human subject in need thereof a prophylactically or therapeutically effective regimen , the regimen comprising the administration of a proliferation based therapy to the human subject , wherein the regimen results in at least an approximately 10% reduction in cancer cells , wherein the proliferation based therapy comprises the administration of:(i) an immunotherapeutic;(ii) a therapeutic, wherein when a therapeutic is administered the proliferation based therapy does not include the administration of a taxane, an alkylating agent or a platinum based chemotherapeutic; or(iii) radiation therapy.2. The method of claim 1 , wherein: (a) the regimen results in an approximately 25% reduction claim 1 , an approximately 40% reduction claim 1 , an approximately 50% reduction or an approximately 75% reduction in the cancer cells; (b) the reduction in the cancer cells is determined by comparing the amount of cells with a cancer cell marker phenotype present in a tissue sample from the human subject to the amount of cells with the same cancer cell marker phenotype present in a tissue sample from the same human subject at an earlier time point; and/or (c) the regimen further comprises monitoring the cancer cells and/or ...

SLOW INTRAVENTRICULAR DELIVERY

Neurological diseases, including lysosomal storage diseases, can be successfully treated using intraventricular delivery of the therapeutic agents to bypass the blood-brain barrier. Similarly, diagnostic agents and anesthetic agents can be delivered to the brain in this manner. The administration can be performed slowly to achieve maximum effect. Such administration permits greater penetration of distal portions of the brain.

METHOD OF TREATMENT USING INHIBITORS OF MITOSIS

Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the second dose is administered 24 to 48 hours after the first dose. 147-. (canceled)48. A method of treating cancer by administering to a patient in need thereof two doses of (S)-2-(3-aminopropyl)-5-(2 ,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1 ,3 ,4-thiadiazole-3(2H)-carboxamide an inhibitor of mitosis selected from the group consisting of the '161 KSP Inhibitors between the biologically effective dose and the maximum tolerated dose in a 14 to 21 day dosing cycle , wherein the first dose is administered on day one of the dosing cycle and the second dose is administered on day two or day three of the dosing cycle.49. A method of claim 48 , wherein the dosing cycle is 14 days.50. A method of claim 48 , wherein the dosing cycle is 21 days.51. A method of claim 49 , wherein the second dose is administered on day two of the dosing cycle.52. A method of claim 50 , wherein the second dose is administered on day two of the dosing cycle.53. A method of claim 49 , wherein the second dose is administered on day three of the dosing cycle.54. A method of claim 50 , wherein the second dose is administered on day three of the dosing cycle.55. A method of claim 51 , wherein the two doses are at the maximum tolerated dose.56. A method of claim 52 , wherein the two doses are at the maximum tolerated dose.57. A method of claim 53 , wherein the two doses are at the maximum tolerated dose.58. A method of claim 54 , wherein the two doses are at the maximum tolerated dose.5970-. (canceled)71. A method of claim 55 , wherein the cancer is a hematological tumor.72. A method of claim 56 , wherein the cancer is a hematological tumor.73. A method of claim 57 , wherein the cancer is a ...

Cardiac arrest muscle relaxant

Muscle Relaxants for Cardiac Arrest Patients

Burner with Adjustable End Cap and Method of Operating Same

A boiler system comprises a housing with a generally cylindrical shape extends between first and second walls to provide a generally cylindrical space. A fire tube is positioned near a bottom of the generally cylindrical housing and extends longitudinally from a first wall of the cylindrical housing to a fire tube end wall. The boiler system also includes a burner with a generally cylindrical housing which defines a generally cylindrical chamber and an end plate. The burner extends into the fire tube, and the fire tube provides a combustion chamber where combustion of an air-fuel mixture is accomplished using the burner. The end plate of the burner is adjustable so as to adjust the flame that extends from within the burner housing into the fire tube. 1. A boiler system comprising:a housing having a generally cylindrical shape and extending between first and second walls to provide a generally cylindrical space;a fire tube positioned near a bottom of the generally cylindrical housing and extending longitudinally from a first wall of the cylindrical housing to a fire tube end wall, a burner having a generally cylindrical housing and an end plate, the housing defining a generally cylindrical chamber;wherein the fire tube provides a combustion chamber where combustion of an air-fuel mixture is accomplished using the burner, the burner extending into the fire tube; andwherein the end plate of the burner is adjustable so as to adjust a flame that extends from within the burner housing into the fire tube.2. The boiler system of further comprising a set of tubes located above a portion of the fire tube and generally spanning a length extending between the first and the second walls of the cylindrical housing.3. The boiler system of claim 2 , further comprising a chamber providing a space between and connecting the fire tube and the set of tubes.4. The boiler system of claim 3 , wherein heated combustion gases flow from the fire tube claim 3 , through the chamber space claim ...

USE OF IBOGAINE AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN

This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL. 1. A method for treating pain in a patient , comprising administering to the patient a dosage of ibogaine , an ibogaine derivative , or a pharmaceutically acceptable salt and/or solvate thereof that provides an average serum concentration of about 50 ng/mL to about 500 ng/mL , said concentration being sufficient to alleviate and/or inhibit said pain while maintaining a QT interval of less than about 500 ms during said treatment.2. The method of claim 1 , wherein the ibogaine claim 1 , an ibogaine derivative claim 1 , or a pharmaceutically acceptable salt and/or solvate thereof is administered as a single dose or multiple doses.3. The method of claim 1 , wherein the aggregate dosage of ibogaine claim 1 , an ibogaine derivative claim 1 , or a pharmaceutically acceptable salt and/or solvate thereof is selected from the group consisting of from about 1.3 mg/kg to about 4 mg/kg per day claim 1 , about 1.5 mg/kg to about 3 mg/kg per day claim 1 , about 2 mg/kg to about 4 mg/kg per day claim 1 , from about 2 mg/kg to about 3 mg/kg per day claim 1 , and about 2 mg/kg per day.4. The method of claim 1 , wherein the dosage of ibogaine claim 1 , an ibogaine derivative claim 1 , or a pharmaceutically acceptable salt and/or solvate thereof provides an average serum concentration of about 50 ng/mL to about 200 ng/mL.5. A method for alleviating pain symptoms in a human patient susceptible to such symptoms claim 1 , comprising administering to the patient a dosage of ibogaine claim 1 , an ibogaine derivative claim 1 , or a pharmaceutically acceptable salt and/or solvate thereof that provides an average serum concentration of about 50 ng/mL to about 400 ng/mL claim 1 , said ...

LOW DOSE NORIBOGAINE FOR TREATING NICOTINE ADDICTION AND PREVENTING RELAPSE OF NICOTINE USE

This invention provides methods and compositions for treating nicotine addiction or treating or preventing nicotine cravings in a subject. The method comprises administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof. 1. A method for treating nicotine addiction in a patient in need thereof , comprising administering to the patient a therapeutically effective amount of noribogaine , noribogaine derivative , or a pharmaceutically acceptable salt thereof , wherein said therapeutically effective amount is from about 50 ng to less than 10 μg per kg body weight per day.2. The method of claim 1 , wherein the therapeutically effective amount is from about 50 ng to about 1 μg per kg body weight per day.3. The method of claim 1 , wherein the noribogaine claim 1 , noribogaine derivative claim 1 , or pharmaceutically acceptable salt thereof is administered by sublingual claim 1 , intranasal claim 1 , or intrapulmonary delivery.4. The method of claim 1 , wherein the therapeutically effective amount is administered once a day.5. The method of claim 1 , wherein the therapeutically effective amount is administered two or more times per day.6. A pharmaceutical composition comprising a therapeutically effective amount of noribogaine claim 1 , noribogaine derivative claim 1 , or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient claim 1 , wherein the therapeutically effective amount of noribogaine claim 1 , noribogaine derivative claim 1 , or pharmaceutically acceptable salt thereof is an amount that delivers an aggregate amount of noribogaine of about 50 ng to less than 10 μg per kg body weight per day.7. The pharmaceutical composition of claim 6 , wherein the therapeutically effective amount of noribogaine claim 6 , noribogaine derivative claim 6 , or pharmaceutically acceptable salt thereof is an amount that delivers an aggregate amount of ...

Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome

The present invention relates to a method of treating or preventing symptoms of irritable bowel syndrome in a mammal, including a human, using a compound that is an NK-1 receptor antagonist, in particular a substance P receptor antagonist.

Use of systemically administrable water-soluble antioxidant

Use of systemically administrable water-soluble antioxidant (I) in the treatment or prophylaxis of inflammatory dermatoses, is new. Independent claims are also included for: (1) use of (I) in combination with systemic administrable lipid-soluble antioxidants (II) in the treatment and prophylaxis of inflammatory dermatoses; and (2) use of systemically administrable N-acetylcysteine in the treatment and prophylaxis of inflammatory dermatoses.

Wireless communications system integrating electronics into orally ingestible products for controlled release of active ingredients

Various embodiments of the present disclosure include a consumable capsule containing an active ingredient in at least one compartment movably sealed by a stimuli responsive actuator, and an activation device configured to communicate with the consumable capsule. The activation device is configured to emit a wireless signal to activate the stimuli responsive actuator of the consumable capsule, and the consumable capsule is configured to release the active ingredient into an external environment based on the activation of the stimuli responsive actuator.

Methods of treatment using an inhibitor of epidermal growth factor receptor

The invention provides methods for treating a variety of cell proliferative diseases using an EGFR inhibitor.

[UNK]

Steam generating system

A steam generating system comprising an enlarged water tank receiving an elongated fire tube therethrough. The fire tube has a burner and steam coil mounted on a movable frame therein and selectively retractable therefrom into an enclosed control room provided at one end of the water tank and including controls, pump means, cleaning means, and the like. The fire tube acts so as to preheat the water subsequently pumped from the tank and through the steam generating coil for ultimate discharge from the system.

Heating device

FIELD: power engineering. SUBSTANCE: heating device comprises the first channel, where a non-ignited gas is burnt, containing fuel, injected with speed of a flow from a nozzle hole, having a smaller size compared to the distance of flame extinguishing, so that in this manner flame is maintained, at the same time providing for a flow of a combustion gas generated as a result of ignition process, the second channel arranged around the first channel and providing for a flow of a non-ignited gas, supplied through the specified nozzle hole, and the third channel, surrounded with the first channel and providing for supply of a liquid to be heated. EFFECT: stabilisation of flame in a combustion chamber and increased energy recovery of a heating device. 8 cl, 13 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 482 388 (13) C2 (51) МПК F22B 7/02 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2010137815/06, 04.03.2009 (24) Дата начала отсчета срока действия патента: 04.03.2009 (56) Список документов, цитированных в отчете о поиске: JP 2000-028109 А, 25.01.2000. RU 2216696 С1, 20.11.2003. RU 2253067 С1, 27.05.2005. RU 2196278 С2, 10.01.2003. FR 2188118, А, 18.01.1974. 2 4 8 2 3 8 8 R U (86) Заявка PCT: JP 2009/054076 (04.03.2009) C 2 C 2 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 04.10.2010 (87) Публикация заявки РСТ: WO 2009/110509 (11.09.2009) Адрес для переписки: 129090, Москва, ул.Б.Спасская, 25, стр.3, ООО "Юридическая фирма Городисский и Партнеры", пат.пов. А.В.Мицу, рег.№ 364 (54) НАГРЕВАТЕЛЬНОЕ УСТРОЙСТВО (57) Реферат: Изобретение относится к теплоэнергетике и может быть использовано в нагревательных устройствах для нагрева жидкости. Сущность изобретения в том, что нагревательное устройство включает первый канал, в котором сжигается невоспламененный газ, содержащий горючее топливо, нагнетаемый со скоростью потока из сопельного отверстия, имеющего меньший размер, чем расстояние пламягашения, ...

燃焼火炎中に吸熱水管を配設したボイラの燃焼空間部構造

(57)【要約】 【課題】 従来の炉筒煙管ボイラ等では炉筒内で燃料を 燃焼させた後、即ち燃焼が完了した後に、燃焼ガスは煙 管を通り外部に排出される構造である為、ボイラ全体に 占める炉筒部の必要空間が大きかった点を改善し小型化 と効率改善等を図る。 【解決手段】 従来ボイラの燃焼空間部の構造では、燃 焼火炎を水管にぶっつけると未燃分のが発生と水管の燃 損が伴なうとの考えの下に、水管を燃焼火炎中に配置す ることは長年禁止されていたが、本発明では、燃料が燃 焼する燃焼火炎中に収熱水管を配設するか、又はボイラ のバーナ近傍の収熱水管の一部分を省いて燃焼火炎中に 多数の収熱水管を設け、収熱水管群中で燃焼と伝熱作用 との２つの作用を行わせる。

Technique for lagophthalmos surgery

FIELD: medicine. SUBSTANCE: to eliminate the paralytic lagophthalmus, a preparation of botulinum toxin (botulinum toxin) type A is used, which is used as "Disport" in the amount of 20-45 ED or "Botox" or "Lantox" or "Xiamin" in the amount of 8-18 ED. The dose of the selected preparation is divided into 2 equal parts and each part is administered in three equal portions along the pupillary line, medially and laterally with distance 0.5 cm. In this case, one part is injected under the upper edge of the orbit to a depth of 1.0-1.5 cm, and the other part - in the region of the upper conjunctival arch to a depth of 0.5-1.0 cm. EFFECT: obtaining a dosed therapeutic effect depending on the severity of the paralytic lagophthalmus and the patient's gender identity, as well as the removal of asymmetry in the position of the eyebrows and overhanging of the eyelid, associated with the omission of the soft tissues of the face on the side of the lesion. 3 cl, 6 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 620 248 C1 (51) МПК A61K 31/00 (2006.01) A61K 9/08 (2006.01) A61P 27/02 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ФОРМУЛА (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ 2016102704, 28.01.2016 (24) Дата начала отсчета срока действия патента: 28.01.2016 Дата регистрации: Приоритет(ы): (22) Дата подачи заявки: 28.01.2016 (45) Опубликовано: 23.05.2017 Бюл. № 15 C 1 2 6 2 0 2 4 8 2521352 C1, 27.06.2014. RU 2405476 C1, 10.12.2010. US 5542437 A, 06.08.1996. МАРИНИЧЕВА И.Г. Хирургическая коррекция паралитического лагофтальма. Автореферат дисс. к.м.н. - М., 1999, с.12-21. (54) Способ устранения паралитического лагофтальма (57) Формула изобретения 1. Способ устранения паралитического лагофтальма, включающий инъекцию препарата токсина ботулизма типа А, отличающийся тем, что в качестве токсина ботулизма типа А используют «Диспорт» в количестве 20-45 единиц (ЕД) или «Ботокс» или «Лантокс» или «Ксиамин» в количестве 8- ...

Method of producing angioprotective and nootropic agents

FIELD: biotechnology.SUBSTANCE: invention refers to biotechnology and medicine, namely to producing an angioprotective and nootropic agent in the form of a solid dosage form for oral administration. Method involves separate granulation of 150–600 mg of troxerutin and 5–10 mg of vinpocetine by mixing each of them with a filler selected from polyethylene glycol-6000, sorbitol or mixtures thereof, until homogeneous, mixing with 1–5 % binder solution, selected from sodium salt of carboxymethyl starch, polyethylene oxide, followed by drying in a fluidised bed at temperature of 100 °C, after which the obtained granules are powdered with at least one antifriction agent, such as aerosil, tween-80, magnesium stearate, and pressed to obtain a solid dosage form.EFFECT: invention widens the range of equipment.3 cl, 2 tbl, 4 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 710 716 C1 (51) МПК A61K 31/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 31/00 (2019.08) (21)(22) Заявка: 2018137653, 25.10.2018 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): Генералов Василий Олегович (RU) Дата регистрации: 10.01.2020 Приоритет(ы): (22) Дата подачи заявки: 25.10.2018 (45) Опубликовано: 10.01.2020 Бюл. № 1 2 7 1 0 7 1 6 R U (54) СПОСОБ ПОЛУЧЕНИЯ АНГИОПРОТЕКТОРНОГО И НООТРОПНОГО СРЕДСТВА (57) Реферат: Изобретение относится к области выбранного из натриевой соли биотехнологии и медицины, а именно к карбоксиметилкрахмала, полиэтиленоксида, с получению ангиопротекторного и ноотропного последующей сушкой в псевдоожиженном слое средства в виде твердой лекарственной формы при температуре 100 °С, после чего опудривают для перрорального введения. Способ включает полученные гранулы, по крайней мере, одним раздельное гранулирование 150-600 мг антифрикционным агентом, таким как аэросил, троксерутина и 5-10 мг винпоцетина путем твин-80, магния стеарат, и прессуют для смешения каждого из них с наполнителем, ...

Нагревательное устройство

1. Нагревательное устройство, содержащее ! первый канал, в котором сжигается невоспламененный газ, содержащий горючее топливо, нагнетаемый со скоростью потока из сопельного отверстия, имеющего меньший размер, чем зона тушения пламени, чтобы, таким образом, обеспечить поддержание пламени, в результате создавая поток газа сгорания, образованного в результате процесса сжигания; и ! второй канал, обеспечивающий поток невоспламененного газа, подаваемого через упомянутое сопельное отверстие. ! 2. Нагревательное устройство по п.1, которое дополнительно содержит третий канал, окруженный первым каналом и обеспечивающий подачу подлежащей нагреву жидкости, и в котором второй канал выполнен вокруг первого канала. ! 3. Нагревательное устройство по п.2, в котором третий канал образован внутренним пространством третьей трубы, причем первый канал образован пространством между третьей трубой и первой трубой, концентрически охватывающий третью трубу, и второй канал образован пространством между первой трубой и второй трубой, концентрически охватывающий первую трубу. ! 4. Нагревательное устройство по п.3, в котором от внешней периферийной поверхности третьей трубы отходит множество ребер, проходящих в направлении первого канала. ! 5. Нагревательное устройство по п.3, в котором третья труба изогнута в сторону первого канала и в сторону второго канала на заданный интервал. ! 6. Нагревательное устройство по п.3, содержащее второй канал, первый канал, выполненный вокруг второго канала, и третий канал, обеспечивающий поток подлежащей нагреву жидкости и образованный вокруг первого канала. ! 7. Нагревательное устройство по п.6, содержа РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2010 137 815 (13) A (51) МПК F22B 7/02 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2010137815/06, 04.03.2009 (71) Заявитель(и): АйЭйЧАй КОРПОРЕЙШН (JP) Приоритет(ы): (30) Конвенционный приоритет: 04.03.2008 JP 2008-053001 04.03.2008 JP 2008-053903 A Адрес для ...

Heater of liquid and gaseous media

FIELD: heat engineering. SUBSTANCE: invention relates to heat engineering and can be used for heating of liquid and gaseous products. Heater of liquid and gaseous media includes a housing filled with liquid intermediate heat carrier, flame tube located on body axis and composed of three cylindrical shells, installed coaxially and forming annular cavities for passage of combustion products, at that in inlet part of a flame tube there is a burner device, which is a circular manifold, on which uniformly along the circumference atmospheric burners with ignition device are located, and in outlet part of the flame tube there is a chimney, heat exchanger made in the form of a coil consisting of two consequently connected sections, pipes of which are parallel to axis of the housing, at that one section of the coil is placed into the inner cavity of the flame tube, and the second is in the annular cavity formed by housing inner surface and outer surface of the flame tube. EFFECT: heating of liquid and gaseous products. 1 cl, 2 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (51) МПК F22B 7/00 (11) (13) 2 600 194 C1 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ На основании пункта 1 статьи 1366 части четвертой Гражданского кодекса Российской Федерации патентообладатель обязуется заключить договор об отчуждении патента на условиях, соответствующих установившейся практике, с любым гражданином Российской Федерации или российским юридическим лицом, кто первым изъявил такое желание и уведомил об этом патентообладателя и федеральный орган исполнительной власти по интеллектуальной собственности. (21)(22) Заявка: 2015133500/06, 10.08.2015 10.08.2015 (73) Патентообладатель(и): Климов Владислав Юрьевич (RU) Приоритет(ы): (22) Дата подачи заявки: 10.08.2015 (56) Список документов, цитированных в отчете о поиске: RU 2256846 C1 20.07.2005;RU 127431 U1 27.04.2013;GB 1379454 A 02.01.1975. FR 2404811 A1 27.04.1979. 2 6 0 0 1 9 4 R U (54) ПОДОГРЕВАТЕЛЬ ...

Heater for track heater

FIELD: heating. SUBSTANCE: invention relates to liquid medium heaters, in particular, to furnaces for track heaters with liquid heat carrier. Heater for track heater is U-shaped tube and is equipped with through overflow tubes arranged in the furnace convection zone at an angle to the horizontal. Through overflow tubes are arranged in staggered order at an angle to horizontal 25–90°, and through diameters outer diameter overflow tubes is 36–70 mm. EFFECT: invention allows reducing temperature of flue gases, increasing surface of heat exchange of convective zone by more than two times, increasing efficiency factor, increasing heat output of track heater. 1 cl, 3 dwg, 1 tbl РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 696 522 C1 (51) МПК F23C 3/00 (2006.01) F22B 7/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК F23C 3/002 (2019.02); F22B 7/00 (2019.02) (21)(22) Заявка: 2018129359, 10.08.2018 (24) Дата начала отсчета срока действия патента: Дата регистрации: 02.08.2019 (45) Опубликовано: 02.08.2019 Бюл. № 22 2 6 9 6 5 2 2 R U (54) Топка для путевого подогревателя (57) Реферат: Изобретение относится к подогревателям жидких сред, в частности к топкам для путевых подогревателей с жидким теплоносителем. Топка для путевого подогревателя представляет собой U-образную трубу и оборудована сквозными переточными трубками, размещенными в конвективной зоне топки под углом к горизонтали. Сквозные переточные трубки расположены в шахматном порядке под углом к Стр.: 1 (56) Список документов, цитированных в отчете о поиске: RU 74190 U1, 20.06.2008. RU 178049 U1, 21.03.2018. KZ 18219 A, 5.01.2007. US 4714052 A1, 22.12.1987. RU 42298 U1, 27.11.2004. RU 160060 U1, 27.02.2016. C 1 C 1 Адрес для переписки: 665835, Иркутская обл., г.Ангарск, ул.Чайковского, 58, АО "АНХП", начальнику Технического отдела Албутовой Е.П. (73) Патентообладатель(и): Акционерное общество "Ангарскнефтехимпроект" (АО "АНХП") (RU) 2 6 9 6 5 2 2 Приоритет(ы): ( ...

Method of producing n-containing bicyclo[4_2_1]nona-2,4,7-trienes exhibiting antitumour activity

Изобретение относится к N-содержащим бицикло[4.2.1]нона-2,4,7-триенам общей формулы (1), к способу получения данных соединений, а также к их применению. Указанные соединения относятся к классу напряженных энергоемких систем и могут найти применение в качестве компонентов высокоэнергетических горючих для воздушно-реактивных ракетных систем, полупродуктов в синтезе современных медицинских препаратов, проявляющих противоопухолевую, противовирусную и другие виды активности. 3 н.п. ф-лы, 2 табл., 2 пр. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 735 662 C1 (51) МПК A61K 31/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 31/00 (2020.05) (21)(22) Заявка: 2019123501, 19.07.2019 (24) Дата начала отсчета срока действия патента: Дата регистрации: 05.11.2020 (45) Опубликовано: 05.11.2020 Бюл. № 31 2 7 3 5 6 6 2 R U (56) Список документов, цитированных в отчете о поиске: Дьяконов В. А. и др. "Синтез Si- и N-содержащих бицикло[4.2.1]нона-2,4-диенов и бицикло[4.2.1]нона-2,4,7-триенов", Известия Академии Наук, Серия химическая, 2013, С. 1015. Vladimir A. D’yakonov et al. "TitaniumCatalyzed [6π+2π]-Cycloaddition of Alkynes and Allenes to 7-Substituted 1,3,5-Cycloheptatrienes", European Journal of Organic Chemistry, (см. прод.) (54) СПОСОБ ПОЛУЧЕНИЯ N-СОДЕРЖАЩИХ БИЦИКЛО[4.2.1]НОНА-2,4,7-ТРИЕНОВ, ПРОЯВЛЯЮЩИХ ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ (57) Реферат: Изобретение относится к N-содержащим компонентов высокоэнергетических горючих для бицикло[4.2.1]нона-2,4,7-триенам общей формулы воздушно-реактивных ракетных систем, (1), к способу получения данных соединений, а полупродуктов в синтезе современных также к их применению. Указанные соединения медицинских препаратов, проявляющих относятся к классу напряженных энергоемких противоопухолевую, противовирусную и другие систем и могут найти применение в качестве виды активности. 3 н.п. ф-лы, 2 табл., 2 пр. (56) (продолжение): 2015, P. 4464-4470. RU 2654201 C1, 17.05.2018. RU 2506085 ...

Method for changing the state of a local skin site

FIELD: medicine. SUBSTANCE: invention relates to medicine, in particular it can be used in cosmetology, dermatology, plastic surgery for the purpose of preventing and slowing the aging of the skin, achieving a rejuvenating effect, eliminating wrinkles on the face. Method for rejuvenating the skin of the face and neck includes injecting the drug, injections are carried out at the exit points of the nerves from the anatomical canals and the facial skull openings and along their length along the nerve fibers with the achievement of the partial neurolysis effect, as a drug substance, a solution consisting of 4 parts of a local anesthetic preparation, 1 part of ethyl alcohol and 0.5 part of a corticosteroid hormone preparation is used. EFFECT: method for rejuvenating the skin of the face and neck is suggested. 1 cl, 1 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 661 018 C1 (51) МПК A61K 31/00 (2006.01) A61P 43/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 31/00 (2006.01); A61K 2121/00 (2006.01) (21)(22) Заявка: 2017136304, 13.10.2017 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): Власян Рубик Ашотович (RU) Дата регистрации: 11.07.2018 (56) Список документов, цитированных в отчете о поиске: RU 2571686 C1, 20.12.2015. RU 2289417 C1, 20.12.2006. RU 2272634 C1, 27.03.2006. (45) Опубликовано: 11.07.2018 Бюл. № 20 R U (54) Способ изменения состояния локального участка кожи (57) Реферат: Изобретение относится к области медицины, анатомических каналов и отверстий лицевого в частности может применяться в косметологии, черепа и на их протяжении по ходу нервных дерматологии, пластической хирургии с целью волокон с достижением эффекта частичного профилактики и замедления старения кожи, нейролиза, в качестве лекарственного вещества достижения омолаживающего эффекта, применяют раствор, состоящий из 4 частей устранения морщин на лице. Способ омоложения препарата местно-анестезирующего ...

Controlled release formulations for oral administration

A pharmaceutical composition in the form of an oral controlled release solid dosage form comprising an effective amount of drug, or its pharmaceutically acceptable salts. It also relates to apharmaceutically composition that is suitable for once-a-day dosing regimen

A controlled release intravaginal polymeric pharmaceutical dosage form

Boiler device and method for operating said device

FIELD: thermal power engineering. SUBSTANCE: invention relates to thermal power engineering and can be used in boiler devices. In a flame and smoke tube boiler having at least one main part (20) with at least two tubes (22, 24), respectively a flame and smoke tube connected with a chamber (40), and a closing device (50), which closes at least the chamber (40) in order to move the closing device (50) in at least one mode relative to the main part (20) in a corresponding direction (62) of movement, the boiler is provided with a moving mechanism (60). EFFECT: technical result is simple and/or rapid disconnection of the main part and the closing device, and the efficiency with which the mounting space is used. 13 cl, 8 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 746 389 C2 (51) МПК F22B 7/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК F22B 7/00 (2021.01) (21)(22) Заявка: 2017139922, 16.11.2017 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): РОБЕРТ БОШ ГМБХ (DE) Дата регистрации: 13.04.2021 Приоритет(ы): (30) Конвенционный приоритет: 17.11.2016 DE 102016222654.1 (43) Дата публикации заявки: 16.05.2019 Бюл. № 14 (45) Опубликовано: 13.04.2021 Бюл. № 11 2 7 4 6 3 8 9 R U (54) КОТЕЛЬНОЕ УСТРОЙСТВО И СПОСОБ ЕГО ЭКСПЛУАТАЦИИ (57) Реферат: Изобретение относится к теплоэнергетике и перемещения закрывающего приспособления (50) может быть применено в котельных устройствах. в по меньшей мере одном режиме относительно В жаротрубно-дымогарном котле, имеющем по основной части (20) в соответствующем меньшей мере одну основную часть (20) с по направлении (62) перемещения, котел снабжают меньшей мере двумя трубами (22, 24), перемещающим механизмом (60). Технический соответственно жаровой и дымогарной результат - простое и/или быстрое разъединение соединенных между собой камерой (40), и основной части и закрывающего приспособления, закрывающее приспособление (50), которое эффективность ...

Fire-tube vertical hot water liquid fuel boiler

FIELD: hot water supply.SUBSTANCE: invention relates to water heating and hot water supply systems. A fire-tube vertical hot water liquid fuel boiler containing a vertical bundle of fire pipes installed inside an external pipe, pipes for direct and reverse mains water, a furnace with vortex steam-oil burner devices installed in it. The boiler contains steam generators of the pipe-in-pipe system with spiral and annular channels installed inside the heat pipes with the possibility of supplying superheated water vapor from one steam generator to the same number of steam nozzles of the burner devices, in order to maintain an equal mass flow rate of the outgoing steam from each nozzle. Steam-oil combustion provides waste-free burning of liquid fuel.EFFECT: creation of a fire-tube vertical liquid fuel hot water boiler that does not have soot and coke deposits on the heat exchange surfaces during operation.1 cl, 4 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 754 619 C1 (51) МПК F24H 1/28 (2006.01) F22B 7/00 (2006.01) F22B 7/02 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК F24H 1/28 (2021.05); F22B 7/00 (2021.05); F22B 7/02 (2021.05) (21)(22) Заявка: 2020139486, 02.12.2020 (24) Дата начала отсчета срока действия патента: Дата регистрации: 06.09.2021 (45) Опубликовано: 06.09.2021 Бюл. № 25 (54) ЖАРОТРУБНЫЙ ВЕРТИКАЛЬНЫЙ ВОДОГРЕЙНЫЙ ЖИДКОТОПЛИВНЫЙ КОТЁЛ (57) Реферат: Изобретение относится к водяным системам возможностью подачи перегретого водяного пара отопления и горячего водоснабжения. из одного парогенератора в одинаковое Жаротрубный вертикальный водогрейный количество паровых форсунок горелочных жидкотопливный котел, содержащий устройств, для сохранения равного массового вертикальный пучок жаровых труб, расхода истекающего пара из каждой форсунки. установленных внутри внешней трубы, патрубки Паромасляное горение обеспечивает бессажное прямой и обратной сетевой воды, топку, с сжигание жидкого топлива. Техническим ...

Water-tube boiler for the production of steam and hot-water

내용 없음. No content.

Novel use

A method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of an NK3 receptor antagonist, wherein the condition characterised by altered bowel function and/or visceral pain is selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain.

Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney

The present invention is directed to KIM-1 polypeptide as a plasma acute and chronic kidney injury and renal cell carcinoma biomarker, and methods and kits comprising the use of agents specific to KIM-1 for facilitating and enhancing the diagnosis of kidney injury or carcinoma. The present invention is based on the discovery that measuring KIM-1 levels in the blood is more accurate and reliable than measuring KIM-1 levels in the urine for the diagnosis of subjects with proximal kidney tubule injury or kidney cancer. The invention is directed to methods for diagnosis of acute kidney injury, chronic kidney disease (CKD), and renal cell cancer by determining and monitoring the levels of KIM-1 polypeptide in a blood sample, such as plasma or serum sample.

Method for combined production of 1-methyl-substituted bicyclo[4_2_1]nona-2,4,7-trienes exhibiting antitumour activity

FIELD: chemistry. SUBSTANCE: invention relates to 1-methyl-substituted bicyclo[4.2.1]nona-2,4,7-trienes of general formula (1) and (2), a method of producing said compounds, as well as use thereof. EFFECT: said compounds belong to a class of intense energy-intensive systems and can be used as components of high-energy combustible for air-jet rocket systems, semi-products in synthesis of modern medical preparations exhibiting anti-tumor, antiviral and other types of activity. 3 cl, 2 ex, 2 tbl РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 735 663 C1 (51) МПК A61K 31/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 31/00 (2020.05) (21)(22) Заявка: 2019123502, 19.07.2019 (24) Дата начала отсчета срока действия патента: Дата регистрации: 05.11.2020 (45) Опубликовано: 05.11.2020 Бюл. № 31 2 7 3 5 6 6 3 R U (56) Список документов, цитированных в отчете о поиске: Дьяконов В. А. и др. "Синтез Si- и N-содержащих бицикло[4.2.1]нона-2,4-диенов и бицикло[4.2.1]нона-2,4,7-триенов", Известия Академии Наук, Серия химическая, 2013, С. 1015. Vladimir A. D’yakonov et al. "TitaniumCatalyzed [6π+2π]-Cycloaddition of Alkynes and Allenes to 7-Substituted 1,3,5-Cycloheptatrienes", European Journal of Organic Chemistry, (см. прод.) (54) СПОСОБ СОВМЕСТНОГО ПОЛУЧЕНИЯ 1-МЕТИЛ-ЗАМЕЩЕННЫХ БИЦИКЛО[4.2.1]НОНА2,4,7-ТРИЕНОВ, ПРОЯВЛЯЮЩИХ ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ (57) Реферат: Изобретение относится к 1-метил-замещенным компонентов высокоэнергетических горючих для бицикло[4.2.1]нона-2,4,7-триенам общей формулы воздушно-реактивных ракетных систем, (1) и (2), к способу получения данных соединений, полупродуктов в синтезе современных а также к их применению. Указанные соединения медицинских препаратов, проявляющих относятся к классу напряженных энергоемких противоопухолевую, противовирусную и другие систем и могут найти применение в качестве виды активности. 3 н.п. ф-лы, 2 пр., 2 табл. (56) (продолжение): 2015, P. 4464-4470. RU 2654201 C1, ...

Patent RU2017139922A3

ВУ"? 2017139922” АЗ Дата публикации: 21.01.2021 Форма № 18 ИЗПМ-2011 Федеральная служба по интеллектуальной собственности Федеральное государственное бюджетное учреждение ж 5 «Федеральный институт промышленной собственности» (ФИПС) ОТЧЕТ О ПОИСКЕ 1. . ИДЕНТИФИКАЦИЯ ЗАЯВКИ Регистрационный номер Дата подачи 2017139922/12(069417) 16.11.2017 Приоритет установлен по дате: [ ] подачи заявки [ ] поступления дополнительных материалов от к ранее поданной заявке № [ ] приоритета по первоначальной заявке № из которой данная заявка выделена [ ] подачи первоначальной заявки № из которой данная заявка выделена [ ] подачи ранее поданной заявки № [Х] подачи первой(ых) заявки(ок) в государстве-участнике Парижской конвенции (31) Номер первой(ых) заявки(ок) (32) Дата подачи первой(ых) заявки(ок) (33) Код страны 1. 192016222654.1 17.11.2016 РЕ Название изобретения (полезной модели): [Х] - как заявлено; [ ] - уточненное (см. Примечания) КОТЕЛЬНОЕ УСТРОЙСТВО И СПОСОБ ЕГО ЭКСПЛУАТАЦИИ Заявитель: РОБЕРТ БОШ ГМБХ, РЕ 2. ЕДИНСТВО ИЗОБРЕТЕНИЯ [Х] соблюдено [ ] не соблюдено. Пояснения: см. Примечания 3. ФОРМУЛА ИЗОБРЕТЕНИЯ: [Х] приняты во внимание все пункты (см. Примечания) [ ] приняты во внимание следующие пункты: [ ] принята во внимание измененная формула изобретения (см. Примечания) 4. КЛАССИФИКАЦИЯ ОБЪЕКТА ИЗОБРЕТЕНИЯ (ПОЛЕЗНОЙ МОДЕЛИ) (Указываются индексы МПК и индикатор текущей версии) Е22В 7/00 (2006.01) 5. ОБЛАСТЬ ПОИСКА 5.1 Проверенный минимум документации РСТ (указывается индексами МПК) Е22В7/00, 7/12, 7/16, 9/00 - 9/14, 5.2 Другая проверенная документация в той мере, в какой она включена в поисковые подборки: 5.3 Электронные базы данных, использованные при поиске (название базы, и если, возможно, поисковые термины): СМГРА, РЕРАТБ пес, ЕВЗСО, Ебрасепе, боозе, ]-Р1а Рае КТРК$, РАТЕМТЗСОРЕ, Ра беагсВ, Оцез{е]-Огри, КОРТО, ИЗРТО 6. ДОКУМЕНТЫ, ОТНОСЯЩИЕСЯ К ПРЕДМЕТУ ПОИСКА Кате- Наименование документа с указанием (где необходимо) частей, Относится к гория* относящихся к предмету поиска ...

A heating medium boiler having combustor reducing nitrogen oxide

본 발명은 중심에 연료노즐이 형성되며, 완전히 분리된 복수 개의 연료노즐에 의한 복수 개의 소형 연료희박/연료농후 화염(fuel lean/fuel rich flame)을 연소기 끝단 단면 전체에 형성하여, 화염에서 생성되는 배기가스가 재순환되는 질소산화물(NOx)을 최소화하는 연소기를 포함하는 열매체 보일러에 관한 것으로 단순한 구성으로써 주변 장치를 필요로 하지 않으면서 기본적인 연소시스템을 구현할 수 있 효과 및 소형의 분할 화염을 통한 열 분산과 화염온도 저하, 각 소형화염들의 최적화된 공연비 화염 형성 및 빠른 연소반응 유도를 통해 질소산화물(NOx)을 현저히 저감시킬 수 있는 효과가 있다. In the present invention, a fuel nozzle is formed at the center, and a plurality of small fuel lean / fuel rich flames formed by a plurality of completely separated fuel nozzles are formed at the entire end surface of the combustor, thereby generating a flame. Thermal heating boiler including a combustor that minimizes NOx to which exhaust gas is recycled. Simple structure, which can realize basic combustion system without the need for peripheral device. Heat dissipation through small split flame There is an effect that can significantly reduce the nitrogen oxides (NOx) through the reduction of the flame temperature, the formation of optimized air-fuel ratio flame of each small flame and the rapid combustion reaction.

Complex preparation for prevention and treatment of broiler chicken hepatosis

FIELD: veterinary science. SUBSTANCE: invention refers to veterinary medicine, particularly to a complex preparation for prevention and treatment of broiler chicken hepatosis. Complex preparation contains: larch bioflavonoid complex — 0.02 mg/g; vitamin A — 500 IU/g; vitamin D 3 — 250 IU/g; vitamin E — 0.2 mg/g. EFFECT: invention provides higher safety and productivity of broiler chickens. 1 cl, 1 tbl РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 767 620 C1 (51) МПК A61K 31/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 31/00 (2022.01) (21)(22) Заявка: 2021120090, 08.07.2021 (24) Дата начала отсчета срока действия патента: Дата регистрации: 18.03.2022 (45) Опубликовано: 18.03.2022 Бюл. № 8 2 7 6 7 6 2 0 R U (56) Список документов, цитированных в отчете о поиске: ШУМАКОВА О. О. Влияние биофлавоноидного комплекса лиственницы на гематологические показатели, естественную резистентность и продуктивность сельскохозяйственной птицы. Автореф. диссерт. на соискание уч. степени кандидата биол. наук. Белгород, 2015. RU 2762221 C1, 16.12.2021. RU 2701567 C1, 30.09.2019. RU 2418601 C2, 20.05.2011. CN 101612360 B, (см. прод.) (54) Комплексный препарат для профилактики и лечения гепатозов цыплят-бройлеров (57) Реферат: Изобретение относится к ветеринарной лиственницы - 0,02 мг/г; витамин А - 500 МЕ/г; медицине, в частности к комплексному препарату витамин D3 - 250 МЕ/г; витамин Е - 0,2 мг/г. для профилактики и лечения гепатозов цыплятИзобретение обеспечивает повышение бройлеров. Комплексный препарат содержит в сохранности и продуктивности цыплятсвоем составе: биофлавоноидный комплекс бройлеров. 1 табл. (56) (продолжение): 21.07.2010. Стр.: 1 C 1 C 1 Адрес для переписки: 308503, Белгородская обл., Белгородский р-н, п. Майский, ул. Вавилова, 24, ФГБОУ ВО Белгородский ГАУ, И.В. Руснак (73) Патентообладатель(и): Федеральное государственное бюджетное образовательное учреждение высшего образования "Белгородский ...

5-HT3 receptor antagonists for the treatment of autism

The invention relates to the use of a compound which acts as an antagonist of 5-HT at 5-HT 3 receptors in the treatment of autism or another disorder originating in childhood in which there is mental retardation.

Remote power-generating assembly

一种与海洋烃类开采和运输工作相关的远程动力供应系统包括产生系统动力的膨胀涡轮。所述远程动力供应系统还具有支撑所述膨胀涡轮的支撑结构。冷却段由所述支撑结构支撑并与所述膨胀涡轮流体连通，用于接收来自所述膨胀涡轮的蒸汽并将其冷凝成液体。下导管和锅炉段与所述冷却段流体连通以接收由蒸汽冷凝成的液体。点火组件朝向下导管和锅炉段的下端部定位。点火组件点燃燃料和空气混合物并且使从冷却段由下导管和锅炉段接收的液体沸腾成蒸汽。回流通道将蒸汽从下导管和锅炉段输送至膨胀涡轮进口。

Nootropic composition based on polypeptide complexes recovered from neuronal progenitor cells under hypoxic conditions, and a method for production thereof

FIELD: biochemistry. SUBSTANCE: invention relates to biochemistry, in particular to a method for preparing a nootropic composition based on polypeptide complexes recovered from neuronal progenitor cells under hypoxic conditions, as well as to a nootropic composition based on polypeptide complexes recovered from neuronal progenitor cells under hypoxic conditions. Said composition is characterized by that it contains proteins and polypeptides with molecular weight from 5 kDa to 250 kDa, cerebral neurotrophic factor (BDNF) of at least 130 pg/ml and a glial neurotrophic factor (GDNF) of at least 30 pg/ml, vascular endothelium growth factor (VEGF) of not less than 90 pg/ml, total protein weight of not less than 1 mg/ml of the preparation. Cell culture of neuronal progenitor cells from which the composition is produced demonstrates neuronal expression β-tubulin III, molecules of adhesion of nerve cells (PSA-NCAM) and consists of 95±5 % TUBB3+ cells. EFFECT: invention enables to efficiently obtain a protein-peptide composition, which includes not only small peptides, but also full-length protein neuronal growth and differentiation factors, the effectiveness of which is certainly higher than that of short peptides, and immunogenicity is absent. 2 cl, 4 ex, 2 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 732 600 C1 (51) МПК C12N 5/095 (2010.01) A61K 31/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C12N 5/00 (2020.02); A61K 31/00 (2020.02) (21)(22) Заявка: 2019144078, 26.12.2019 (24) Дата начала отсчета срока действия патента: Дата регистрации: 21.09.2020 (45) Опубликовано: 21.09.2020 Бюл. № 27 Адрес для переписки: 115478, Москва, ул. Москворечье, 1, Гольдштейн Дмитрий Вадимович C 1 2 7 3 2 6 0 0 R U (56) Список документов, цитированных в отчете о поиске: RU2690498 C1, 04.06.2019. RU2690846 C1, 06.06.2019. WO2001088104 A2, 16.05.2001. US6455277 B1, 24.09.2002. (54) Ноотропная композиция на основе полипептидных ...

Heating system for home which use solar heat

본 발명은 태양열을 이용한 공동주택 개별 난방 및 급탕시스템에 관한 것으로서, 공동주택 개별 난방 및 급탕시스템에 있어서, 태양열을 집열시키는 태양열 집열기와, 태양열 집열기로부터 공급순환라인이 연결되어 태양열 집열기를 통해 열 교환이 이루어지는 판형 열교환기와, 판형 열교환기로부터 공급 및 순환라인으로 연결되어 열 교환된 온수를 저장하여 축열하는 태양열 축열조와, 상기 태양열 축열조로부터 축열된 온수를 공동주택 측으로 공급 및 환원시키는 공급순환라인을 포함하여 구성된 태양열 공급부와; 상기 태양열 공급부와는 개별적으로 화석에너지를 연소시켜 열 에너지를 얻기 위한 보일러 및 보일러의 가동을 제어하는 보일러 컨트롤러와, 상기 보일러를 경유하여 온수를 유통시키는 물 공급라인 및 물 공급라인상에 설치되어 외부로부터 물공급에 의한 물 공급상태를 감지하는 물흐름감지센서와, 상기 보일러를 경유하는 물 공급라인과 태양열 축열조에서 온수를 공급하는 공급순환라인측과 열 교환이 이루어지도록 연계되어 설치되는 판형 열교환기와, 상기 태양열 축열조에서 온수를 공급하는 공급순환라인에 설치되어 온수순환을 위한 순환펌프 및 온수사용에 따른 전력사용량으로 환산하는 적산열량계와, 상기 태양열 축열조에서 온수를 공급하는 공급순환라인에 설치되어 온수온도를 감지하는 온도감지기와, 상기 온도감지기, 물흐름감지센서 및 보일러 컨트롤러와 전기적으로 배선되어 온수의 설정온도에 따라 보일러 컨트롤러의 가동을 제어하는 마이컴으로 이루어진 공동주택 개별난방부 및 급탕부;로 구성된 것을 특징으로 하는바, 태양열을 이용하여 축열된 온수의 온도설정에 따라 개인주택에 마련된 보일러를 비난방 혹은 자동으로 난방할 수 있도록 한 것으로, 태양열 축열조로부터 열교환하여 난방하거나 일반적인 보일러를 통한 온수공급 또는 난방수를 병행하여 난방과 급탕할 수 있는 이점이 있으며, 난방운영과 급탕운영에 따른 에너지를 현저히 절감하는 효과와 함께 대기환경오염을 현저히 줄이는 이점을 제공하는 효과가 있다. [0001] The present invention relates to an individual heating and hot water supply system for a multi-family house using solar heat, comprising: a solar heat collector for collecting solar heat; and a circulation line for supplying heat from the solar collector, And a supply circulation line for supplying and reducing the hot water stored in the solar heat storage tank to the side of the apartment house, and a circulation line for circulating the hot water from the solar heat storage tank A solar heating unit having a plurality of solar heaters; A boiler controller for controlling the operation of the boiler and the boiler for burning fossil energy separately from the solar heat supply unit, a water supply line for circulating the hot water through the boiler, A water flow sensor for sensing a water supply state by water supply from the water supply line, a water supply line through the boiler, and a supply circulation line for supplying hot water in the solar heat storage tank, A circulation pump ...

The device and method of operation of the traveling oil heater

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2015 129 868 A (51) МПК F22B 7/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2015129868, 21.07.2015 (71) Заявитель(и): Беляев Андрей Юрьевич (RU), Виленский Леонид Михайлович (RU) Приоритет(ы): (22) Дата подачи заявки: 21.07.2015 (43) Дата публикации заявки: 25.01.2017 Бюл. № 03 R U Адрес для переписки: 125368, Москва, а/я 84, Щитову А.А. (72) Автор(ы): Беляев Андрей Юрьевич (RU), Виленский Леонид Михайлович (RU) Стр.: 1 2 0 1 5 1 2 9 8 6 8 R U A (57) Формула изобретения 1. Устройство путевого подогревателя нефти, характеризуемое тем, что оно содержит корпус, содержащий герметично закрытую полость, в нижней части полости расположен первый трубчатый теплообменник, предназначенный для прохождения дымовых газов, входной и выходной штуцеры которого расположены на корпусе, в полости расположен второй трубчатый теплообменник, предназначенный для нагрева нефти, подключенный в патрубкам ввода и вывода нефти, закрепленным на корпусе, в нижней части полости находится жидкий теплоноситель. 2. Устройство по п. 1, отличающееся тем, что трубчатый теплообменник дымовых газов погружен в жидкий теплоноситель. 3. Устройство по п. 1, отличающееся тем, что поверхность корпуса покрыта слоем теплоизоляции. 4. Устройство по п. 1, отличающееся тем, что корпус установлен горизонтально. 5. Способ работы путевого подогревателя нефти, характеризуемый тем, что подогрев нефти, проходящей по первому трубчатому теплообменнику, расположенному в герметично закрытой полости, осуществляют путем конденсации на внешней поверхности теплообменника парообразного теплоносителя, жидкая фаза которого расположена в нижней части полости, а подогрев жидкого теплоносителя осуществляют путем приложения к жидкой фазе тепловой энергии от дымовых газов, проходящих через второй трубчатый теплообменник. 6. Способ по п. 5, отличающийся тем, что в качестве жидкого теплоносителя используют водно-органические смеси, ...

Tubular heater

FIELD: heating. SUBSTANCE: invention relates to heating devices for fluids, namely to fire heaters, and can be used in oil, chemical and other industries for the heat treatment of thermolabile and thermally unstable liquids having technological and other limitations on the maximum heating temperature. Tubular heater comprising a flame tube with turbulence rings arranged therein, a convection chamber, a burner device adjoining an end of the flame tube, a jacket in which an intermediate heat carrier is placed and a section of a process coil made of successively connected tube-pins with interwoven ribbons inserted therein, which is connected in series with another section of the process coil placed in a convection chamber and made of serially connected tube-pins, on the outer surface of which there is a spiral winding, is characterized in that the convection chamber is located in a portion of the flame tube opposite to the burner device, in the flame tube at an angle to the horizontal, there are additionally placed tubes that open ends enter the shirt, in addition, the body cylindrical elements of the heater are made detachable for the possibility of extracting sections of the process coil and the convenience of carrying out repair works. EFFECT: technical problem solved by the invention consists in simplifying the design, increasing the efficiency and reliability of the tubular heater operation. 1 cl, 6 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 655 096 C1 (51) МПК F22B 7/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК F22B 7/00 (2006.01) (21)(22) Заявка: 2017124506, 10.07.2017 (24) Дата начала отсчета срока действия патента: Дата регистрации: 23.05.2018 Приоритет(ы): (22) Дата подачи заявки: 10.07.2017 (56) Список документов, цитированных в отчете о поиске: RU 2256846 C1, 20.07.2005. RU (45) Опубликовано: 23.05.2018 Бюл. № 15 2 6 5 5 0 9 6 R U (54) ТРУБЧАТЫЙ ПОДОГРЕВАТЕЛЬ (57) Реферат: Изобретение ...

A kind of boiler heating system with supplying hot water and heating function

一种具有供热水及供暖功能的锅炉供热系统，包括锅炉、锅炉出水管、锅炉回水管、生活热水供水系统与供暖系统，所述锅炉出水管的第一分支连接所述生活热水供水系统，所述锅炉出水管的第二分支连接所述供暖系统。本发明的具有供热水及供暖功能的锅炉供热系统包括生活热水供水系统与供暖系统，管路设计合理，管路简便，利用同一锅炉即可实现供热水与供暖，能源利用率高。

BOILER DEVICE AND METHOD OF ITS OPERATION

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2017 139 922 A (51) МПК F22B 7/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2017139922, 16.11.2017 (71) Заявитель(и): РОБЕРТ БОШ ГМБХ (DE) Приоритет(ы): (30) Конвенционный приоритет: (72) Автор(ы): ФРАНК Кристиан (DE) 17.11.2016 DE 102016222654.1 Адрес для переписки: 105082, Москва, Спартаковский пер., 2, стр. 1, секция 1, этаж 3, ЕВРОМАРКПАТ Стр.: 1 A 2 0 1 7 1 3 9 9 2 2 R U A (57) Формула изобретения 1. Котельное устройство, прежде всего устройство жаротрубно-дымогарного котла, имеющее по меньшей мере одну основную часть (20) с по меньшей мере двумя трубами (22; 24), прежде всего с по меньшей мере одной жаровой трубой и по меньшей мере одной дымогарной трубой, по меньшей мере одну камеру (40), которая соединяет между собой указанные по меньшей мере две трубы (22; 24), и по меньшей мере одно закрывающее приспособление (50), которое закрывает по меньшей мере камеру (40), отличающееся наличием перемещающего механизма (60), который предназначен для перемещения закрывающего приспособления (50) в по меньшей мере одном режиме относительно основной части (20) в соответствующем направлении (62) перемещения. 2. Котельное устройство по п. 1, отличающееся тем, что камера (40) выполнена в виде поворотной камеры. 3. Котельное устройство по п. 1 или 2, отличающееся тем, что направление (62) перемещения по меньшей мере в основном параллельно направлению (38) продольной протяженности основной части (20). 4. Котельное устройство по одному из предыдущих пунктов, отличающееся тем, что перемещающий механизм (60) содержит опорное приспособление (70) для опирания на него закрывающего приспособления (50). 5. Котельное устройство по п. 4, отличающееся тем, что опорное приспособление (70) расположено в направлении силы тяжести по меньшей мере частично под закрывающим приспособлением (50). 6. Котельное устройство по п. 4 или 5, отличающееся тем, что опорное приспособление (70) имеет по ...

Means of correction and prevention of conditions caused by violation of daily rhythms

FIELD: pharmacology. SUBSTANCE: invention relates to chemical and pharmaceutical industry and is a means of correcting and preventing desynchronosis states comprising compounds of the general formula: where R is COCH 2 CH 2 COOH, COCH 2 NH 2 , COCH 2 (NH 2 )CH 2 CH 2 COOH, COCH 2 NHCOCH 2 (NH 2 )CH 2 CH 2 COOH or EFFECT: invention allows to achieve high efficiency of the new agent for improving the body's adaptation to changes in daily rhythms and the treatment of disorders caused by various desynchronizing factors. 1 cl, 7 tbl, 10 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 655 813 C1 (51) МПК A61K 31/00 (2006.01) A61K 31/405 (2006.01) A61P 25/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 31/00 (2006.01); A61K 31/405 (2006.01); A61K 2121/00 (2006.01) (21)(22) Заявка: 2017120452, 09.06.2017 (24) Дата начала отсчета срока действия патента: Дата регистрации: 29.05.2018 (45) Опубликовано: 29.05.2018 Бюл. № 16 Адрес для переписки: 192019, Санкт-Петербург, ул. Бехтерева, 1, ФГБУН ИТ ФМБА России (56) Список документов, цитированных в отчете о поиске: Garaeva L. D., et al. Synthesis of C 1 Modified Purine Ribonucleosides from 3'(5")O-succinyladenosine and 5'-Amino-5'deoxyadenosine // Russian Journal of Bioorganic Chemistry. - 1995. - Vol. 21, N 9. P. 619-625. Soriano-Agaton, Flor, et al. Extraction, hemisynthesis, and synthesis of canthin-6-one analogues. Evaluation of their antifungal (см. прод.) R U (54) Средство коррекции и профилактики состояний, вызванных нарушением суточных ритмов (57) Реферат: Изобретение относится к химикоCOCH2NHCOCH2(NH2)CH2CH2COOH или фармацевтической промышленности и представляет собой средство коррекции и профилактики состояний десинхроноза, содержащее соединения общей формулы: где R представляет собой СОСН2СН2СООН, COCH2(NH2)CH2CH2COOH, Стр.: 1 C 1 2 6 5 5 8 1 3 2 6 5 5 8 1 3 (73) Патентообладатель(и): Федеральное государственное бюджетное учреждение науки "Институт ...

Controlled release formulations for oral administration

A pharmaceutical composition in the form of an oral controlled release solid dosage form comprising an effective amount of drug, or its pharmaceutically acceptable salts. It also relates to a pharmaceutically composition that is suitable for once-a-day dosing regimen.

Treatment of conditions through modulation of the autonomic nervous system

Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is pharmacologically modulated with at least one aldosterone antagonist in a manner that is effective to treat the subject for the condition. Also provided are systems and kits for use in practicing the subject methods.

Novel method of treatment

A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof, of an effective non-toxic amount of an insulin sensitiser so as to provide a plasma concentration of the insulin sensitiser of at least a threshold level (the “Threshold Plasma Concentration”) from within the range of effective plasma levels of the insulin sensitiser, compositions for use in such method and methodology for determining plasma concentrations of active agent use in such methods.

Composition for embolization and hyperthermia of vascular tumors

FIELD: medicine.SUBSTANCE: invention relates to medicine, new embolizing agents, and discloses a composition for embolizing vascular tumors followed by hyperthermia. Composition consists of dimethyl vinyl polysiloxane, oligodimethylsiloxane, oligohydride siloxane, catalyst and magnetic particles, it additionally contains 1,3,5,7-tetravinyl-1,3,5,7-tetramethylcyclotetrasiloxane, as magnetic particles – magnetite nanoparticles, and as a catalyst – platinum [0]-vinyl-containing complex.EFFECT: composition can be used in the treatment of cancer patients by intraorganic local arterial occlusion of tumor vessels; use of this composition improves the conditions of embolization of the vessels, leads to a reliable stopping of the blood supply of the tumor tissue and the possibility of using the thermotherapy of the tumor.1 cl РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 670 446 C1 (51) МПК A61K 31/00 (2006.01) A61K 31/695 (2006.01) A61K 8/25 (2006.01) A61K 8/89 (2006.01) A61L 31/12 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 31/00 (2018.08); A61K 31/695 (2018.08); A61K 8/025 (2018.08); A61K 8/89 (2018.08); A61L 31/12 (2018.08) (21)(22) Заявка: 2017127907, 03.08.2017 03.08.2017 Дата регистрации: 23.10.2018 2 6 7 0 4 4 6 Адрес для переписки: 197758, Санкт-Петербург, пос. Песочный, ул. Ленинградская, 70, ФГБУ "Российский научный центр радиологии и хирургических технологий им. академика Гранова", Черепановой В.П. (73) Патентообладатель(и): Федеральное государственное бюджетное учреждение "Российский научный центр радиологии и хирургических технологий им. академика Гранова" Министерства здравоохранения Российской Федерации (RU), Общество с ограниченной ответственностью "Научно-производственная фирма "Линорм" (RU) (56) Список документов, цитированных в отчете о поиске: RU 2073529, 20.02.1997. SU 1106509 R U A1, 07.08.1984. MOSSO J.A. et al. Ferromagnetic silicone vascular occlusion. A tachnic for selective infarction ...

Alternating-combustion heating boiler

To improve the heat conversion in conjunction with the reduction in the heat losses on alternating-combustion heating boilers, of which the two combustion chambers for solid fuels on the one hand and for oil or gas on the other hand are accommodated in a water-carrying housing, such a boiler is designed, according to the invention, in such a way that transverse ribs (3) are arranged on the underside of the draught floor (1) in the region of the combustion chamber (2) for liquid or gaseous fuels and, adjacent thereto, longitudinal ribs (6) are arranged in the region of the overflow orifice (4) and of the solid-fuel combustion chamber (5), and that the water-carrying walls of the two combustion chambers (3, 5) are made separating in the vertical direction approximately up to the height of the water-carrying draught floor (1). <IMAGE>

steam generator

本发明涉及工业加热设备技术领域，特别是一种应用于工业取暖、烘干和灭菌等行业的蒸汽发生器，该蒸汽发生器采用在加热室内设有均匀分布的多根加热管，并对加热管进行通火加热，同时在加热管外面充满冷却水，使冷却水与加热管充分接触，提高受热面积，达到快速加热的效果，将燃烧室设置在加热室的正下端可以有效的将热量传递到加热管内，燃烧室使用天燃气、液化汽和乙醇等环保形燃料，应用于工业取暖、烘干和蒸汽灭菌等行业，具有加热速度快、加热效果好、环保不污染环境等优点。

Process for the preparation of purified concentrates of the B group vitamins

A heating medium boiler having combustor reducing nitrogen oxide

본 발명은 중심에 연료노즐이 형성되며, 완전히 분리된 복수 개의 연료노즐에 의한 복수 개의 소형 연료희박/연료농후 화염(fuel lean/fuel rich flame)을 연소기 끝단 단면 전체에 형성하여, 화염에서 생성되는 배기가스가 재순환되는 질소산화물(NOx)을 최소화하는 연소기를 포함하는 열매체 보일러에 관한 것으로 단순한 구성으로써 주변 장치를 필요로 하지 않으면서 기본적인 연소시스템을 구현할 수 있 효과 및 소형의 분할 화염을 통한 열 분산과 화염온도 저하, 각 소형화염들의 최적화된 공연비 화염 형성 및 빠른 연소반응 유도를 통해 질소산화물(NOx)을 현저히 저감시킬 수 있는 효과가 있다.

Controlled release oral dosage forms of poorly soluble drugs and uses thereof

Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.

Method for improving the functional operability of patients with lung cancer on the background of copd iii-iv

Изобретение относится к области медицины, а именно к онкологии, пульмонологии, и может быть использовано для улучшения функциональной операбельности у пациентов с раком легкого, диагностированным на фоне хронической обструктивной болезни легкого (ХОБЛ) III-VI степени за счет устранения дисфункции дыхательной и скелетной мускулатуры и улучшения механики дыхания. Для этого на амбулаторном этапе, за две недели до хирургического лечения, назначают выполнение комплекса физических тренировок, включающего циклы дыхательных, силовых и аэробных упражнений. Выполнение комплекса начинают с цикла дыхательных упражнений. Цикл силовых тренировок выполняют с использованием палки или резинки с включением упражнений на верхние и нижние группы мышц. Завершают комплекс выполнением цикла аэробных тренировок, включающих по выбору пациента ходьбу, велотренажер или плавание. Комплекс упражнений подбирают индивидуально в зависимости от физического статуса пациента и выполняют ежедневно на протяжении двух недель. Способ обеспечивает сокращение времени лечения, а также улучшение показателей функциональной операбельности у больных раком. 1 пр. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 757 799 C1 (51) МПК A61K 31/00 (2006.01) A61B 5/00 (2006.01) A61B 1/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 31/00 (2021.08); A61B 5/00 (2021.08); A61B 1/00 (2021.08) (21)(22) Заявка: 2021106182, 11.03.2021 (24) Дата начала отсчета срока действия патента: Дата регистрации: 21.10.2021 (45) Опубликовано: 21.10.2021 Бюл. № 30 2 7 5 7 7 9 9 R U (56) Список документов, цитированных в отчете о поиске: RU 2735722 C1, 06.11.2020. RU 2464006 C2, 20.10.2012. RU 2513418 C1, 19.12.2012. КОТОВА Т. Г. ОПРЕДЕЛЕНИЕ ФУНКЦИОНАЛЬНОЙ ОПЕРАБЕЛЬНОСТИ ПРИ ОДНОВРЕМЕННЫХ ДВУСТОРОННИХ РЕЗЕКЦИЯХ ЛЕГКИХ ПО ПОВОДУ ДВУСТОРОННЕГО ТУБЕРКУЛЕЗА ЛЕГКИХ // Международный журнал прикладных и фундаментальных исследований. - 2018. - N 12-2. - С. 240-245. ПАРШИН В.Д. и др. (см. ...

Industrial hot water boiler

FIELD: thermal engineering. SUBSTANCE: present invention relates to a thermal engineering. Water boiler consisting of an external casing, a burner, a gas collector, a chimney, characterized in that inside the combustion chambers installed on I-beams, the cores are arranged with the help of plugs, while the heat passes between the walls of the combustion chambers and the walls of the cores, and the heat pipes emanate from the combustion chambers at an angle and exit into the gas sump. EFFECT: invention is aimed at increasing the heated surface and maximizing the use of heat. 1 cl, 4 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 658 445 C1 (51) МПК F24H 1/00 (2006.01) F22B 7/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК F24H 1/00 (2017.08); F22B 7/00 (2017.08) (21)(22) Заявка: 2017108062, 10.03.2017 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): Бадоев Александр Сергеевич (RU) Дата регистрации: 21.06.2018 61012 U1, 10.02.2007. RU 2159893 C2, 27.11.2000. RU 2499187 C1, 20.11.2013. (45) Опубликовано: 21.06.2018 Бюл. № 18 2 6 5 8 4 4 5 R U (54) ПРОМЫШЛЕННЫЙ ВОДОГРЕЙНЫЙ КОТЕЛ (57) Реферат: Настоящее изобретение относится к тепловой при этом жар проходит между стенками топочных технике. Водогрейный котел, состоящий из камер и стенками сердечников, а жаровые трубы внешнего корпуса, горелки, газосборника, исходят от топочных камер под углом и выходят дымохода, отличающийся тем, что внутри в газосборник. Изобретение направлено на топочных камер, установленных на двутавровые увеличение обогреваемой поверхности и балки, устроены сердечники с помощью заглушек, максимальное использование жара. 4 ил. Стр.: 1 C 1 C 1 Адрес для переписки: 362049, РСО-Алания, г. Владикавказ, ул. Васо Абаева, 87, к. 6, кв. 28, Бадоеву Александру Сергеевичу 2 6 5 8 4 4 5 (56) Список документов, цитированных в отчете о поиске: CN 101576317 A, 11.11.2009. RU Приоритет(ы): (22) Дата подачи заявки: 10.03.2017 R U ...

Nootropic composition based on polypeptide complexes isolated from neuronal progenitor cells under heat shock and method for production thereof

FIELD: biotechnology. SUBSTANCE: invention relates to the field of biotechnology, particularly to a method for producing a nootropic composition based on polypeptide complexes isolated from neuronal progenitor cells under heat shock. Said composition is characterised by the fact that it contains proteins and polypeptides with a molecular weight from 3 kDa to 250 kDa, 60% whereof have a molecular weight in the range from 10 to 50 kDa, brain-derived neurotrophic factor (BDNF) no less than 120 pg/ml, and glial cell line-derived neurotrophic factor (GDNF) no less than 40 pg/ml, vascular endothelial growth factor (VEGF) not less than 60 pg/ml, total protein weight no less than 1 mg/ml of the preparation. The cell culture of neuronal progenitor cells therein, wherefrom the composition is produced, demonstrates the expression of a β3-tubulin neuronal marker, a nerve cell adhesion molecule (PSA-NCAM), and consists of 99.5±2.45% TUBB3 + cells. EFFECT: invention allows effectively producing a protein-peptide composition including not only small peptides, but also full-size protein neuronal growth and differentiation factors the effectiveness whereof is invariably higher than in short peptides and immunogenicity is not present. 2 cl, 2 dwg, 4 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 752 906 C2 (51) МПК C12N 5/095 (2010.01) A61K 31/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C12N 5/00 (2020.02); A61K 31/00 (2020.02) (21)(22) Заявка: 2019144080, 26.12.2019 (24) Дата начала отсчета срока действия патента: Дата регистрации: 11.08.2021 (43) Дата публикации заявки: 28.06.2021 Бюл. № 19 (45) Опубликовано: 11.08.2021 Бюл. № 23 2 7 5 2 9 0 6 R U (73) Патентообладатель(и): Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" (RU) (56) Список документов, цитированных в отчете о поиске: RU2690846 C1, 06.06.2019. RU2690498 C1, 04.06.2019. WO2001088104 ...